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INTRODUCTION 
Acinetobacter calcoaceticus-baumannii is a non fermenting gram negative bacilli or 
cocco bacilli belonging to the family Moraxellaceae. It is a ubiquitous organism found in 
soil, sewage, and dry surfaces (1, 2). They can be readily isolated from areas of moist 
skin such as toe webs, groin, and the axilla. The organism can be identified from hospital 
equipment such as ventilators, curtains, telephones, door handles(2). It was until recently, 
dismissed as a non pathogen, contaminating clinical specimens. Of late the organism has 
been recognized as a nosocomial pathogen and has been, increasingly so, in patients 
admitted in intensive care units, on mechanical ventilation and on central venous 
catheters. It has emerged as a leading cause of Ventilator Associated pneumonia (VAP) 
(3, 4).  The organism has low virulence potential, but with the emergence of multidrug 
and pan drug resistant strains, this organism has emerged as a leading cause of mortality, 
morbidity, and increased hospital cost and duration of hospitalization (5, 6).  In the year 
1984, Acinetobacter spp. was classified in the family Neisseriaceae, but more recently 
the molecular taxonomic studies have resulted in the reclassification of the organism in 
the new family of Moraxellaceae in 1991(7). 
The gold standard for definitive identification of the species of these bacteria is by DNA-
DNA hybridization. This is available only in reference laboratories. Most of the clinical 
laboratories report the organisms as belonging to ‘Acinetobacter calcoaceticus-
A.baumannii complex’ or the sacchrolytic Acinetobacter and includes A.baumannii, 
A.calcoaceticus, Acinetobacter genomospecies 3, and Acinetobacter genomospecies 
13TU and as the non sacchrolytic Acinetobacter spp based on bio-chemical reactions. 
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A.baumannii is the most commonly isolated from the sacchrolytic group and A.lwoffii is 
the most common isolated from the non sacchrolytic group(7).  
The drugs most effective in the early 80’s, were the common anti pseudomonal 
cephalosporin, namely ceftazidime and cefotaxime. This was later replaced by the 
carbapenem group of drugs- imipenem and meropenem. By the early 1990s, there was 
resistance reported to this class of antibiotics as well. Over the years the, resistance to 
various class of anti microbial agents, has shown an upward trend across various studies 
done across the world and thus this organism has emerged as an important pathogen 
amongst the nosocomial infections. The resistance rate varies from 14% to as high as 
30%. A study conducted in Christian Medical College, Vellore has shown an incidence of 
14.2%(8).   
This has prompted a search for effective drugs for treating infections caused by 
carbapenem resistant   A. baumannii. They may be classified as  
1. Drugs of renewed interest-Polymyxins and Sulbactam. 
2. Newer drugs-Tigecycline. 
 Polymyxins act by disrupting the cell membrane. These drugs, though discovered in the 
1980’s, had fallen into disrepute due to severe nephrotoxicity. With the increased 
isolation of pan drug resistant strains, the use of this drug has been evaluated. The various 
in vitro and clinical use of this drug has shown the efficacy of this drug in combating the 
Multidrug and Pan drug resistant strains (9, 10). 
 Sulbactam has shown intrinsic activity against Acinetobacter spp., and has been shown 
to be effective  as a mono therapeutic agent in clinical trials conducted in Spain and 
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Germany(11). Though not available as a single drug, it is available in combination with 
Cefeperazone and Ampicillin. 
Tigecycline belonging to the tetracycline group of drugs acts via the inhibition of protein 
synthesis. The susceptibility to Tigecycline has varied in various reports across the world. 
No studies have been done in India, evaluating the efficacy of this drug in our isolates 
 Various mechanisms have been described by which Acinetobacter spp. mediates 
resistance to carbapenem group of drugs. This includes efflux pumps, loss of porin 
channel, and the most important being the production of various β-lactamases(4). Various 
classes of these enzymes have been detected in Acinetobacter spp., but the most 
widespread of them all belong to the class D group in the Ambler classification-the 
Oxacillinases. The oxacillinases are classified into nine major groups and each of these 
groups has many subtypes in them. The most wide spread of these enzymes is the OXA-
51 enzyme, which is found to be present in all isolates of A. baumannii. This enzyme has 
been evaluated to be a molecular marker for rapid identification of this organism, from 
clinical isolates. The gene for this enzyme is present on the chromosome of 
A.baumannii(12). The other most wide spread and well documented enzyme is the OXA-
23. This enzyme is mediated via transposons. Also integrons have been described in 
Acinetobacter spp., the most important class found in Acinetobacter spp. is Class I. These 
integrons encode for resistance against different class of antimicrobial agents. Thus 
dissemination of these genes has made this organism resistant to all commonly available 
antibiotics, making the treatment options severely limited. 
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Aim 
To detect the various genes those encodes for carbapenem resistance in clinical isolates 
of A.baumannii and ascertain the molecular marker for rapid detection for the same. 
Objectives 
1. To identify A.baumannii phenotypically. 
2. To evaluate OXA-51 for identification of A.baumannii. 
3. To determine the gene encoding for carbapenem resistance (OXA-51 and OXA-
23). 
4. To determine the prevalent antimicrobial susceptibility profile among our study 
isolates. 
5. To determine the susceptibility of carbapenem resistant A.baumannii to 
Tigecycline by disc diffusion method. 
6. To determine the baseline MIC value for drugs of renewed interest (Polymyxins, 
Sulbactam) against carbapenem resistant nosocomial A.baumannii  
7. To investigate for presence of other resistance genes in representative isolates. 
8. To correlate the outcome in patients infected with carbapenem and Tigecycline 
resistant strains. 
9. To correlate clinically the outcome using Clinical Pulmonary Infection Score 
(CPIS) and Charlson Co-morbidity Index (CCI).  
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REVIEW OF LITERATURE 
Acinetobacter species are gram negative non fermenting coccobacillary organism which 
has been increasingly implicated in various hospital acquired infections, leading to 
increased hospital stay, morbidity, mortality. 
3.1 The organism 
The Acinetobacter species are common free living saprophytes found in soil, water, 
sewage, and food products like pasteurized milk. They are known to survive for weeks on 
clothing, dry surfaces such as bed rails, ventilators, and curtains (1, 13).  
3.1.1 Classification  
The organism is encapsulated, aerobic, non fermentative gram negative short rods and on 
isolation from clinical materials can be frankly coccobacillary. The organism was  
classified(7, 13), first as Diplococcus, and then has been subsequently name as 
Micrococcus, Mima, and Achromobacter. The first strains of Acinetobacter spp were 
isolated by M.W. Beijerinck in 1911 from soil and were named as Micrococcus 
calcoaceticus. In 1954, J.Brisou and A.R. Prevot created the genus Acinetobacter. The 
word ‘Acinetobacter’ derived from Greek meaning non motile, bringing together Gram 
negative saprophytes which do not produce pigments-the Tribe Achromobactereae, and 
also those which are non motile. In the year 1971, the Subcommittee on the Taxonomy of 
Moraxella and Allied Bacteria proposed that the genus Acinetobacter should include only 
the oxidase negative strains.  In the year 1984, Bergey’s Manual of Systematic 
Bacteriology classified Acinetobacter in the family Neisseriaceae, but more recently the 
molecular taxonomic studies have resulted in the reclassification of the organism in the 
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new family of Moraxellaceae in 1991. This family also includes Moraxella, 
Psychrobacter and related organisms. The organism based on 16S  rRNA and rDNA-
DNA hybridization assays, is hence classified in the Super family II of the 
Proteobacteria, Family Moraxellaceae, Genus Acinetobacter (13).  
The genus was further subdivided into 12 genomospecies, by Bouvet and Grimont in 
1986 based on DNA-DNA hybridization and nutritional characteristics(7). Further in the 
year 1989, the number of genomospecies was increased to 17. But some of the same 
genomospecies had different phenotypic characters; hence different DNA groups had 
same number. This lead to lot of confusion regarding the nomenclature of the organism at 
the species level. The type species is genomospecies 1 – A.calcoaceticus and this is 
primarily isolated from soil.  The genomospecies 2 is A.baumannii and includes those 
species which were formerly classified as Herella vaginicola and then as A.calcoaceticus 
var. anitratus. Other organisms are A.hemolyticus (genomospecies 4), A.junii 
(genomospecies 5), A.johnsonii (genomospecies 7), and A.lwoffii (genomospecies 8). The 
rest of the species remained unnamed. Majority of these are non pathogenic to man, and 
hence most of the clinical laboratories report the organisms as belonging to 
‘Acinetobacter calcoaceticus-baumannii complex’ or the ‘sacchrolytic Acinetobacter’ 
and the non sacchrolytic organisms as the ‘non sacchrolytic Acinetobacter’.  A baumannii 
is the most commonly isolated from the sacchrolytic group and A.lwoffii is the most 
common isolated from the non sacchrolytic group. 
3.1.2. Morphology and cultural characteristics 
The organism is described as being short, plump, Gram negative rods typically 0.9-
1.6X1.5-2.5µm in the logarithmic phase of growth, but often becoming more coccoid in 
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the stationary phase. The cell wall structure is typical to that of the gram negative 
bacteria, but the cells are difficult to destain. The cells occur in pairs, but also in chains of 
variable length. No spores are formed and flagella are absent. Although generally 
considered as non motile, ”twitching” or “gliding” motility has been described for some 
strains, especially on semisolid agar.  Many of the strains are encapsulated, and this can 
be readily seen on India Ink preparations(13). 
The organism is non fastidious in its growth requirements and will grow freely on 
ordinary simple media without any enrichment. The members of this genus are strictly 
aerobic and can grow at a wide range of temperatures. Most strains will grow at 33ºC, but 
some environmental isolates will grow 20-30ºC.  The clinical isolates of Acinetobacter 
will normally grow at 37ºC, and some strains even at 42ºC.  After 24 hours, the colonies 
are between 0.5-2mm in diameter; opaque to translucent, usually non pigmented, but 
some strains form white to cream colored colonies, which vary in consistency from 
butyrous to smooth and mucoid.  The organism grows well on MacConkey agar, and 
produce faint pink colonies. 
Some specific media have been described for selective enrichment, from soil and water-
liquid enrichment culture (Baumann’s Enrichment Medium), and differential isolation 
can be done on an antibiotic- containing selective solid media. The most commonly used 
is Leeds Acinetobacter Medium, which has been found to be the best for isolating 
Acinetobacter species from environmental and clinical sources. It contains Vancomycin, 
Cefsulodin and Cephradine(13).   
3.1.3 Biochemical characteristics(7) 
 
Organism Genomosp. Urease 
Nitrate 
reduced 
Growth 
at 37ºC 
Growth 
at 44ºC Hemolysis 
OF 
Glucose 
Arginine 
hydrolysis 
Malonate 
utilized 
A.johnsonii 7 - - - - - - V V 
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A.baumannii 2 - - + + - + + + 
A.haemolyticus 4 - - + - + V + - 
A.calcoaceticus 1 - - + - - + + + 
A.junii 5 - - + - - - + - 
A.lwoffii 8/9 - - + - - - - - 
 
The organism is Oxidase negative, showing the absence of cytochrome C and catalase 
positive. The sacchrolytic (A.calocaceticus-baumannii complex) group acidifies most OF 
carbohydrates; in particular, definitive identification is made by demonstrating the rapid 
production of acid from lactose (1% and 10%). In contrast, A.lwoffii is assachrolytic. The 
bio chemicals commonly utilized, in clinical laboratory, are OF glucose, Malonate 
utilization, Arginine dihydrolysis, and Nitrate reduction.         
3.1.4 Virulence factors 
Although the organism is considered a low grade pathogen, certain characteristics which 
it possess, enhance the virulence of this organism in clinical infections (4). 
1. The presence of a polysaccharide capsule made of L-rahmnose, D- glucose, D- 
glucuronic acid and D- mannose which protects the organism against 
phagocytosis and also makes it more hydrophilic. 
2.  The property of adhesion, to human epithelial surfaces due to capsule and 
fimbriae. 
3. The presence of enzymes which damage host lipids. 
4. The presence of lipopolysacchride which like other gram negative organisms is 
lethal to mice, pyrogenic in rabbits, and a positive Limulus ameobocyte lysate 
test. 
5. The production of slime by some strains is important in mixed infection. 
6. The production of iron containing siderophores such as acinetobactin, which 
chelates iron and helps the organism to survive ,under conditions of low iron 
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supply, in humans points to the role of iron in the virulence mechanisms of 
Acinetobacter. 
7. These organisms are frequently resistant to multiple antibiotics used to treat 
nosocomial infection.  
The experimental work done on mice has proven that the organism has low virulence 106 
to 108 is the 50% lethal dose, even in neutropenic mice (14).  
3.1.5 Habitat 
Certain Acinetobacter species are found as normal constituents of the human skin. They 
can be readily isolated from areas of moist skin such as toe webs, groin and the axilla(2, 
4). The organism can be identified from hospital equipment such as ventilators, curtains, 
telephones, door handlers(1). The organisms are ubiquitous and are found in soil, water, 
and sewage. Estimates have shown that Acinetobacter spp. may constitute as much as 
0.001% of the total aerobic population of soil and water. In fresh water ecosystems, they 
have been found to be about 104 organisms per 100 ml(13). 
Acinetobacter spp. has also been isolated from a variety of food stuffs, which include 
various poultry, milk products, and vegetables.  
3.1.6 Industrial use of Acinetobacter species 
Various species of Acinetobacter have been found to elaborate and excrete polymers 
which have found wide ranging utilities in the industry. Some of these polymers are 
“emulsan”, “biodispersan”, “alasan”. The various uses in the industry are 
1. Bioremediation of waste waters and effluents. 
2. Production of biopolymers and bio surfactants- For prevention of dental plaque. 
3. Biomass production- Production of immune adjuvant. 
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4. Clinical uses- Production of glutaminase- asparaginase, Production of   L- 
carnitine. 
 
3.2 Risk factors for acquiring Acinetobacter species infection 
The species which are implicated in clinical disease belong to the sacchrolytic group that 
is the Acinetobacter calcoaceticus-baumannii complex. The other main isolated 
Acinetobacter species from clinical specimens is A.lwoffii.  
Risk factors for acquiring for infections can be divided as community acquired and 
hospital acquired (7). 
The risk for community acquired Acinetobacter spp. infection are alcoholism, cigarette 
smoking, chronic lung disease, diabetes mellitus(2). 
The risk factors for nosocomial infection include length of hospital stay, surgery, 
wounds,  previous infections (independent of antibiotic usage), Fecal  colonization with 
Acinetobacter spp. ,treatment with broad spectrum antibiotics, indwelling central 
intravenous or urinary catheters, admission to a burns unit or intensive care unit, 
parenteral nutrition and mechanical ventilation(2). 
Outbreaks are frequently located in intensive care units and burn units involving patients 
on mechanical ventilation. Sources of transmission which have been identified include 
respiratory equipments such as resuscitator bags, valves, ventilator circuits, suction 
catheters. Other sources include humidifiers, pillows, mattresses, bedpans(2). The 
patients on mechanical ventilation and infected with resistant strains of Acinetobacter 
spp. were at a 21.8% attributable mortality, higher hospitalization costs, and longer ICU 
and hospital stays(15). Acinetobacter pneumonias are characterized by a late onset and 
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though still not clearly implicated in an increased mortality, were definitely linked with a 
longer hospital stay. 
A study reported in India shows that, mechanical ventilation  and a particular 
antimicrobial pattern, i.e. is resistance to ceftazidime, cefotaxime, amikacin, ciprofloxcin, 
ofloxacin contributed to increased mortality in hospitalized patients, infected with 
Acinetobacter spp(16). 
3.3 Antimicrobial Susceptibility pattern for Acinetobacter    
Acinetobacter spp. is inherently resistant to the β-lactam group of drugs.  Till 1984-85, 
the drugs most effective against Acinetobacter infections were ceftazidime (80%) and 
imipenem (100%). Data available from the early 1990’s, showed an increased resistance 
to the cephalosporin and carbapenem group.  This trend continued, through the years and 
the latest data shows that the resistance to ceftazidime is about 50-60% and to imipenem 
is in the range of 20%-30%, thus continues to show an upward trend (17).  Many 
different definitions are present in literature for Multidrug and Pan drug resistant 
Acinetobacter species.  Multidrug resistance is resistance to more than two of the 
following five drug classes: 
• antipseudomonal cephalosporins (ceftazidime or cefepime), 
• antipseudomonal carbapemens (Imipenem or Meropenem), 
• ampicillin-sulbactam, 
• fluoroquinolones (ciprofloxacin or levofloxacin),  
• amino glycosides (gentamicin, tobramycin, or Amikacin).  
Despite "pan-" meaning "all," pan drug resistance is often defined as resistance to all 
antimicrobials that undergo first-line susceptibility testing that have therapeutic 
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potential against A. baumannii. This would include all β-lactams (including 
carbapemens and sulbactam, fluoroquinolones, and amino glycosides. However, with 
the increased use of the Polymyxins and possibly Tigecycline, this definition will 
have to encompass the newer and renewed drugs(4).   
3.4 Epidemiology of Acinetobacter infections 
Acinetobacter spp. are implicated in nosocomial infections and are increasingly difficult 
to treat as majority of the isolates are multidrug or pan drug resistant. The infections are 
being documented with increased frequency over the last few years from centers all over 
the world including India. 
Burden of disease –World wide 
Various studies have shown the isolation of multidrug resistant Acinetobacter spp. 
especially Acinetobacter calcoaceticus-baumannii. The occurrence of imipenem resistant 
ACB complex was first described in the year 1991 in a New York centre and has then 
been increasingly reported from across the continents and has of late become the second 
most common isolate from critically ill patients admitted in the intensive care unit, 
second only to Ps. aeruginosa. 
3.4.1 The Americas 
 The imipenem susceptibility was determined in a surveillance network carried out in the 
USA from January 1994 to June 1998 and it was found that, of 976,927 total isolates 
collected over the study period, there was a year by year increment in the intermediate 
susceptible/completely resistant strains as determined by the NCCLS guidelines. Starting 
from 2.76% there has been an increment to about 5.8% by June 1998(17). The National 
Nosocomial Infection Surveillance system collected data from 1986 to 2003, showed 
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resistance to Imipenem increase from 0% to 20%(4). Another study based in 76 centers 
across USA has revealed a resistance of 39.8%(4). One interesting fact which has come 
to the fore is the rate of Acinetobacter spp. infections in army personnel returning from 
war in Iraq and Afghanistan (3, 15). It was found that war wound infected with 
Acinetobacter spp showed an imipenem resistance of 37%.  In other countries like 
Guatemala, Acinetobacter spp as a cause of ventilator associated pneumonia is described 
to the tune of 17%, second only to Pseudomonas (3). In the Latin American countries a 
resistance of about 39% was estimated in a surveillance program conducted during 2004-
2005(4).  
3.4.2 South Africa 
In South Africa the incidence of Imipenem resistant Acinetobacter spp isolated from 
blood stream infections, was to the tune of 30%.  
3.4.3 European scenario  
It was in Scotland, in the year 1986 that the first carbapenemase enzyme was identified.  
Till the early years of this decade, carbapenem resistance was not a major health problem 
in Europe, with a resistance ranging from 0% in Germany to 2.2% in England (18, 19). 
Since the year 2003, there has been an increase in the isolation of resistant strains which 
has increased over the years. The European isolates are unique in that the various isolates 
are clonally related. There is a southeast clone prevalent in England, and a single clone 
isolated from 55 hospitals in France. In addition to this, there are 3 international 
A.baumannii clones –called as European clones I, II and III, which are prevalent across 
Europe. Carbapenem resistance seems to be highest in the countries of Turkey, Greece, 
Italy, and England and the rates appear to be the least in countries of Germany and The 
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Netherlands. A study published states that  Acinetobacter spp infections most frequently 
involve the respiratory tract of patients on ventilators and Acinetobacter pneumonia is 
more common in critically ill patients in Asian (range 4–44%) and European (0–35%) 
hospitals than in United States hospitals (6–11%). In Europe there is a difference seen in 
different countries regarding the proportion of ICU-acquired pneumonias, caused by 
Acinetobacter spp with low numbers in Scandinavia, and gradually rising in Central and 
Southern Europe. A higher proportion of Acinetobacter spp isolates were resistant to 
amino glycosides and piperacillin/tazobactam in Asian and European countries than in 
the United States(20). 
3.4.4 Asia 
Even in the Far East, there is an increase in Acinetobacter spp infections and those caused 
by carbapenem resistant strains have been documented. In Korea, the incidence of 
resistance has been documented to be 17% (21). The SENTRY study has revealed a rate 
of > 25% for this region in a survey done in 2001-2004. 
 3.4.5 Indian Scenario  
The Indian scenario is not very different from the world scenario. Sporadic reports appear 
in literature as case reports of infections caused by multidrug resistance Acinetobacter 
species. A study done in Amritsar has revealed an incidence of Acinetobacter septicemia 
to be 12.3%. A study published from Christian Medical College, Vellore has documented 
an incidence of 14.2% Acinetobacter strains resistant to carbapenem class of drugs(8). A 
study published from All India Institute of Medical Sciences, New Delhi in 2005 has 
given a prevalence of 34.7% resistance to meropenem and 27.2% resistance in their 
institute(22).  A study published from St. John’s Medical College, Bangalore has shown a 
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resistance of 14%(23). Another study from Chandigarh in 2003 also has shown a 
resistance of 20% (19). 
 
 
 
Author Year In patient/ out patient 
No. of isolates 
tested 
Major drugs 
tested % resistance 
Gupta et al 2006(22) In patient 2626 CZD,CZD+CA, CTX,CTX+CA 27.2% 
Arora et al 2006(24) In patient 108 β-lactams, AG 12.3% 
Gladstone et al 2005(8) In patient 606 β-lactams, AG 14.2% 
Sinha et al 2007(23) Not mentioned 150 
β-lactams, 
AG 14% 
Taneja et al 2003(25) In patients 85 β-lactams, AG 20% 
β-lactam includes penicillin group, β-lactam + β-lactamase inhibitors, Carbapenem, 
Cephalosporins, CTX- Cefotaxime CZD- Ceftazidime, CA- Clavulanic acid, AG- amino 
glycosides. 
3.5 Mechanisms of resistance 
The presence of various mechanisms conferring resistance to the different class of 
antibiotics has been well documented. The various mechanisms are mediated by genes 
which are either chromosomally or plasmid mediated. Various integrons and transposons 
have been detected which encode for various proteins which confer resistance in these 
organisms (26). 
3.5.1 Resistance to Aminoglycosides 
The resistance to amino glycosides is mediated via modifying enzymes which have all 
been found to be located within the class I integrons. The major class of enzymes found 
is acetyltransferases, nucleotidytransferases and phosphotransferases. Also efflux pumps 
have been documented which throw out the antibiotic from within the cell. The pumps 
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which have been implicated in Acinetobacter spp. are AdeABC from the RND class and 
also AbeM from the MATE class. The newest addition is the methylation of 16S r RNA 
from Korea and Japan which confers high level resistance to all amino glycosides. 
 
 
3.5.2 Resistance to Quinolones 
Modification of DNA gyrase or Topoisomerase IV through mutations in the gyrA gene is 
well documented in Acinetobacter calcoaceticus-baumannii complex. Also the efflux 
pumps AdeABC and AdeM are also implicated, in the same.  
3.5.3 Resistance to Other antibiotics 
Resistance to tetracycline is mediated by the ribosomal protection, conferred by the 
tet(A) and tet(B) d genes and also by efflux pumps. Resistance to sulfamethoxazole is 
mediated by sul gene which is found on the 3’ conserved region of an integron(4). The 
presence of sulfa resistance is highly predictive of the isolate carrying integrons. 
Resistance to chloramphenicol and trimethoprim is mediated by cat and dhfr genes 
respectively, all of which are present on integrons. 
3.5.4 Resistance to β- lactam group 
The resistance to beta lactam group of drugs includes both methods which involve the 
presence of enzymes which hydrolyze the beta lactam ring as well as mechanisms which 
lead to decreased concentrations of the drug, i.e. via the efflux pumps The beta lactamase 
or enzymes which cause hydrolysis of the beta lactam ring are classified by two systems.-
Ambler’s classification which is based on amino acid sequences and Bush-Jacoby-
Medeiros classification, which is a functional classification. 
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Ambler’s classification 
 Class A- Penicillinases [TEM, SHV]. 
 Class B- Metallo-ß-lactamases [IMP, VIM].-These need zinc as a moiety for its 
functioning. 
 Class C- Cephalosporinases [AmpC]. 
 Class D- Oxacillinases [OXA-23.OXA-58]. 
Classes A.C, D have a serine moiety at the active site. 
Bush –Jacoby-Medeiros classification(27) 
Group Enzyme Mol. Class Inhibited by Clavulanic Acid. Example 
1 Cephalosporinase C No P99,MIR-1 
2a Penicillinase A Yes S.aureus[B] 
2b Broad spectrum A Yes SHV-1 
2be Extended spectrum A Yes TEM-3 
2br Inhibitor resistant A Diminished TEM-30 
2c Carbenicillinase A Yes CARB-3 
2d Cloxacillinase D or A Yes OXA-1 
2e Cephalosporinase A Yes FEC-1 
2f Carbapenemase A Yes IMC-1 
3 Carbapenemase A No IMP-1 
4 Penicillinase  No SAR-2 
 
 The beta lactamase enzymes are both chromosomally as well as plasmid mediated. The 
AmpC cephalosporinases are chromosomally mediated and are found inherently in all A. 
baumannii strains. These enzymes are active against all beta lactams except cefepime and 
the carbapenem. They have an upstream regulator which is termed as ISAba1 which 
regulates the over expression of this gene(28). 
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Extended spectrum beta lactamase (ESBL) belonging to the Ambler Class A group have 
been described in these organisms. The various enzymes described in this organism are 
VEB-1 from France, PER-1 from Turkey, Belgium, TEM-92, and TEM-116 from Italy 
and SHV-12 from China. The most concerning of the enzymes described so far are the 
carbapenem hydrolyzing enzymes. These include 2 main class of enzymes- Ambler class 
D OXA type (group 2d of the Bush classification), which are the serine oxacillinases and 
are the most widespread and the metallo beta lactamses from the Ambler class B.  
The first oxacillinase to be described with carbapenem hydrolyzing property was from 
Edinburgh, Scotland. It was named as ARI-1(for Acinetobacter resistant to Imipenem) 
and was found to of plasmid origin, was transferable, and was later renamed as blaOXA-23.  
It was found to be of 273 amino acid length showing sequence homology to Ambler class 
D, oxacillin–hydrolyzing enzymes. Two highly conserved motifs, S-T-F-K and K-T-G 
(positions 79 to 82 and 216 to 218), believed to contribute to the function of the serine 
active site, and were also defined. A third motif, F-G-N at positions 152 to 154, which 
differs from the corresponding motif in all other OXA enzymes by the presence of 
phenylalanine instead of tyrosine, was identified. This unique substitution was postulated 
to have significant biochemical effects and was possibly a factor in the evolution of 
carbapenem resistance in Acinetobacter(29). Its biochemical characterization revealed a 
β-lactamase with a pI value of 6.65 and was poorly inhibited by clavulanic acid and 
EDTA. It has been recently determined that the gene for this has been transferred from 
another Acinetobacter species –Acinetobacter radioresistens. It is a commensal found 
commonly on the skin of humans, especially hospitalized patients. The gene was found to 
be chromosomal in this organism and it is hypothesized that A.baumannii first inserted an 
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ISAba-1 element into the genome of the A.radioresistens, and from there it got the 
blaOXA-23 gene on the plasmid (30). Now more than 100 oxacillinase type enzymes have 
been identified in Acinetobacter spp. They are classified as those that occur 
chromosomally mediated and those that are mediated from plasmids. Nine main clusters 
of OXA type enzymes have been identified, which in their own groups have a sequence 
homology of about 92.5 to 99% to each other and 40-70% homology with the enzymes 
from other enzymes (31). Out of the listed below the first four groups, are the most 
implicated in clinical disease. Of them the first three are plasmid mediated, and the fourth 
is intrinsic that is chromosomally mediated. The nine groups are  
1. blaOXA-23   which has 2 other OXA types OXA-27,OXA-49. 
2. blaOXA-24 which has OXA24,25,26,40. 
3. blaOXA-58 .,which is the only one in its group 
4. The fourth group is chromosomally mediated and consists of blaOXA-51 which 
encodes for OXA-51, OXA-64,-65,-66,-69. 
5. OXA-55 
6. OXA-48 which includes OXA-54,-SAR-2 
7. OXA-50 which also includes OXA-50a to OXA-50d,-PoxB 
8. OXA-60a to OXA-60d 
9. OXA-62. 
Of this OXA-51 is of special interest as this has been proposed to be ubiquitous in all A. 
baumannii isolates and is being touted as a molecular marker for the identification of A. 
baumannii(12).  It was first reported from Argentina in the year 2004 and its analysis 
revealed a molecular mass of 35.5 kDa. Ampicillin was found to be the best substrate, 
and slow hydrolysis of imipenem was detected. It was also determined, that the enzyme 
had highest affinity for imipenem as a substrate (32). A study done in England was able 
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to identify the gene in all isolates studied(12). Of further concern is the emergence of two 
distinct clones within the OXA-23 group. A study  done in England, has identified 2 
clones which have a different susceptibility profile, clone 2 being, susceptible to 
amikacin whereas clone 1 was resistant. Minocycline also had only borderline activity 
against clone1 but good activity against clone 2 (33). 
The expression of the above mentioned genes, is dependent on various insertion 
sequences, which act as upstream regulators, the presence of which causes the over 
expression of the genes leading to clinical carbapenem resistance. The insertion 
sequences have a two fold action; firstly they encode for a transposase and hence are 
mobile: secondly they can contain promoter regions that lead to the over expression of 
downstream resistance elements (28). This is especially true about the OXA-23 and 
OXA-58 and may regulate the expression of OXA-51. This also mediates tetracycline 
resistance. 
The other classes of enzymes, important for carbapenem resistance are the metallo beta-
lactamase group of enzymes. These are found within class I integrons in A. baumannii 
and though less described in Acinetobacter spp. isolates are about 100-1000 times more 
potent than OXA type carbapenemases in hydrolysis of carbapemens. The 3 types of 
MBL found in A. baumannii are IMP, VIM, SIM(4).  
 Another important mechanism of multidrug resistance in Acinetobacter spp is integrons. 
Integrons are assembly platforms that incorporate exogenous open reading frames 
(ORFs) by site-specific recombination and convert them to functional genes by ensuring 
their correct expression.  All integrons have three key elements necessary for the capture 
of exogenous genes: a gene (intI) encoding an integrase belonging to the tyrosine-
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recombinase family; a primary recombination site (attI); and an outward- orientated 
promoter (Pc) that directs transcription of the captured genes. Integron-encoded 
integrases can recombine discrete units of circularized DNA known as gene cassettes. 
Integration occurs downstream of the resident Pc promoter at the attI site, allowing 
expression of the genes in the cassette. All integron-inserted gene cassettes identified 
share specific structural characteristics and generally contain a single gene and an 
imperfect inverted repeat at the 3′ end of the gene called an attC site. The attC sites are a 
diverse family of nucleotide sequences that function as recognition sites for the site-
specific integrase. They vary in length from 57 bp to 141 bp, and their nucleotide 
sequence similarities are primarily restricted to the boundaries, which contain conserved 
sequences known as the R′′ sequence and the R′ sequence. At present, five classes of 
mobile integrons are known to have a role in the dissemination of antibiotic-resistance 
genes. These classes have been historically defined based on the sequence of the encoded 
integrases, which show 40–58% identity. All five classes are physically linked to mobile 
DNA elements, such as insertion sequences (ISs), transposons and conjugative plasmids, 
all of which can serve as vehicles for the intraspecies and interspecies transmission of 
genetic material. Three classes of mobile integrons are historical classes that are involved 
in the multiple-antibiotic-resistance phenotype. Class 1 integrons are associated with 
functional and non-functional transposons derived from Tn402 that can be embedded in 
larger transposons, such as Tn21. Class 2 integrons are exclusively associated with Tn7 
derivatives, and class 3 integrons are thought to be located in a transposon inserted in as-
yet-uncharacterized plasmids. Class 1 integrons are found extensively in clinical isolates, 
and most of the known antibiotic-resistance gene cassettes belong to this class. Over 80 
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different gene cassettes from class 1 integrons have been described. Between them, these 
elements confer resistance to all known β-lactams, all aminoglycosides, chloramphenicol, 
trimethoprim, streptothricin, rifampin, erythromycin, fosfomycin, lincomycin and 
antiseptics of the quaternary-ammonium-compound family (34). Study done by Turton et 
al has shown that the Class I integrase was found in all strains in an epidemic outbreak in 
England and have proposed it as a marker for detecting epidemic outbreaks of 
Acinetobacter (26). 
Not all carbapenem resistance is mediated via the various enzymes described, but also 
due to the presence of efflux pumps which actively pump out the antibiotic from the 
internal milieu of the cell. Of significance in carbapenem resistance are two efflux 
pumps- AdeABC from the RND (Resistance –nodulation-division) family and the AbeM 
pump of the MATE (Multidrug and toxic compound extrusion) family (4, 35).  In 
addition, the loss of a porin channel termed as CarO porin which is a 29-kDa protein was 
implicated in resistance to carbapemens. This protein is a novel Outer Membrane Protein, 
which is unique to the Moraxellaceae family (4, 36). 
All the above stated mechanisms can occur singly or in conjugation with each other. The 
most worrisome of this is the fact that the majority of the resistance genes are found on 
transposons and also because of the insertion sequences which carry the genetic 
information for drug resistance across various classes of drugs.  Indiscriminate utilization 
of one class of drugs can lead to expression of resistance to another class of drug. For 
example the presence of genes encoding for MBLs, also has genes encoding for amino 
glycoside resistance so, the over use of carbapemens, can lead to the development of 
resistance to both carbapemens and amino glycosides.  
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3.6 Laboratory Methods to determine Resistance: 
3.6.1 Phenotypic Methods 
Screening methods 
1.According to the CLSI (Clinical and laboratory Standards Institute), break points have 
been laid down to determine the resistance or susceptibility of Acinetobacter spp for 
various antibiotics by the disc diffusion (DD) and minimum inhibitory concentration 
(MIC)(37). According to the January, 2008 document, for a disc strength of 10µg for 
Imipenem and Meropenem, a zone diameter of <13mm as determined by disc diffusion is 
categorized, as resistant. MIC as determined by broth dilution or agar dilution method 
using cation adjusted Mueller-Hinton broth /agar, was interpreted as resistant for values 
of >16µg/ml.  
2. Various automated systems have been evaluated for their efficacy in detecting 
carbapenem resistance. Their pick up rate ranged from 6.7 to 87%. Also E test 
(Epsilometer Test), gave inconsistent results due to presence of colonies in the zone of 
inhibition(4). 
3. A clue for the presence of MBL’s can be got by a susceptibility pattern of a strain 
resistant to all antibiotics except Aztreonam. This is because the action of the MBLs is 
inhibited by Aztreonam. 
4. The presence of the efflux pumps can be determined by the growth of organism in the 
presence of reserpine or xylene. 
Confirmatory tests 
a. A method of detection for the presence of MBLs and carbapenemases is the Modified 
Hodge’s test and the double disc synergy using EDTA instead of a β-lactamase inhibitor. 
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The modified Hodge test uses Escherichia coli ATCC 25922 and 10 μg imipenem disc 
instead of Staphylococcus aureus ATCC 25923 and a 10 μg penicillin disc, 
respectively(38). 
Modified Hodge test is carried out on Mueller-Hinton agar. The plate is inoculated, as a 
lawn culture, with a 1 in 10 dilution of 0.5McFarland adjusted, overnight culture 
suspension of Esc.coli ATCC 25922. After allowing the plate to dry for a while, 10 μg 
Imipenem disc is placed at the center of the plate and test strains are streaked from the 
edge of the disc to the periphery of the plate in four different directions. After overnight 
incubation the plates are observed for the presence of a ‘cloverleaf shaped’ zone of 
inhibition. The plates with such zones are interpreted as modified Hodge test 
positive(38).  
For the EDTA-disk diffusion synergy test an overnight broth culture of the test strain, 
(opacity adjusted to 0.5 McFarland opacity standards) is used to inoculate a plate of 
Mueller-Hinton agar. After drying, a 10 μg imipenem disc and a blank filter paper disk, 
6mm in diameter made from Whatmann filter paper number 2 are placed 10mm apart 
from edge to edge. 10 μl of 0.5 M EDTA solution is then applied to the blank disc, which 
resulted in approximately 1.5 mg/disc. After overnight incubation, the presence of an 
enlarged zone of inhibition is interpreted as EDTA synergy positive(38). The sensitivity 
of this test is 95.7%. Also instead of EDTA, 2-mercatopropionic acid can be used. 
b. E test strips for metallo β-lactamase production are available as imipenem and 
imipenem-EDTA combinations. A positive test for metallo β-lactamase production is 
interpreted as a three fold or decrease in MIC of the imipenem in the presence of EDTA 
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c. Carbapenem inactivation assays are a fast way of detecting carbapenemase activity, 
especially for weakly hydrolyzing enzymes like OXA-23. 
d. The cloverleaf test, where suspensions of whole cells or and/or an extract of the 
suspect isolate are tested against Imipenem on an agar plate. Altered growth of an 
indicator strain (Esc.coli ATCC 25922) around an imipenem disk is a positive result (31).  
e. Iso electric focusing (IEF), is used to separate out proteins, by charge and the detection 
of β-lactamses can be done by using the chromogenic cephalosporin nitrocefin. 
Overlaying of the gel with EDTA, clavulanic acid, or Aztreonam can detect sensitivity of 
the enzyme to these potential inhibitors. IEF is an excellent modality to detect multiple β- 
lactamases in one isolate. IEF can also be used as an bioassay by using an agar overlay 
with Imipenem and a second overlay with a susceptible indicator organism .Growth over 
an enzyme band indicates a potential carbapenemases. This is especially effective in 
detecting those enzymes which have a poor hydrolyzing rate with nitrocefin (31). 
f. Imipenem hydrolysis can be most reliably detected by spectrophotometric 
measurement using crude cell extracts or purified β-lactamases. If a metallo β-lactamase 
is suspected, brief pre incubation with EDTA prior to analysis results in a lower 
hydrolysis rate (31). 
g. Mass spectrometry can be utilized to determine the loss of the 29-kDa porin channel 
3.6.2 Molecular Methods 
Various studies towards the determination of genes responsible for the carbapenem 
resistance have been published. Polymerase Chain Reaction (PCR) is a laboratory 
technique which amplifies a DNA target region, so as to obtain a million or more copies 
which can then be easily visualized by using DNA staining techniques. Many of the 
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genes have been fully sequenced and have been expressed in Esc.coli as part of 
transformation experiments, proving beyond doubt, the role of these enzymes in 
resistance. There are various multiplex polymerase chain reactions, which at the same 
time can detect for different groups of β-lactamase in the same reaction (39). PCR’s have 
been developed which determine the presence of different groups of OXA enzymes in the 
same reaction. Also PCR’s to detect the integrons have been developed (26). PCR is the 
fastest way to determine, which family the beta-lactamase belongs to. 
Enzyme family Primers Primer sequence (5'-3') Fragment size (bp) Reference 
Class D oxacillinases 
P5 AAGCATGATGAGCGCAAAG 1,066 Subgroup 1 (OXA-
23) P6 AAAAGGCCCATTTATCTCAAA  
Donald et 
al(29) 
Forward GTACTAATCAAAGTTGTGAA 1,023 Subgroup 2 (OXA-
24) Reverse TTCCCCTAACATGAATTTGT  
Afzal et 
al(40) 
OXA-69A CTAATAATTGATCTACTCAAG 975 Subgroup 3 (OXA-
69) OXA-69B CCAGTGGATGGATGGATAGATTATC  
Heritier et 
al(41) 
Pre-OXA-58prom+ TTATCAAAATCCAATCGGC 934 Subgroup 4 (OXA-
58) PreOXA-58B TAACCTCAAACTTCTAATTC  
Heritier et 
al(42) 
TAATGCTTTGATCGGCCTTG 353 
OXA-51-like 
TGGATTGCACTTCATCTTGG  
GATCGGATTGGAGAACCAGA 501 
OXA-23-like 
ATTTCTGACCGCATTTCCAT  
GGTTAGTTGGCCCCCTTAAA 246 
OXA-24-like 
AGTTGAGCGAAAAGGGGATT  
AAGTATTGGGGCTTGTGCTG 599 
Multiplex PCR for 
OXAs in A. 
baumannii 
OXA-58-like 
CCCCTCTGCGCTCTACATAC  
Woodford et 
al(39) 
Class B metalloenzymes 
SIM1-F TACAAGGGATTCGGCATCG 571 
SIM-1 
SIM1-R TAATGGCCTGTTCCCATGTG  
Lee et al(43) 
Integron PCR 5' CS GGCATCCAAGCAGCAAG Variable Turton et al(26) 
 3' CS AAGCAGACTTGACCTGA   
3.7 Treatment modalities for Multi drug resistant and Pan drug 
resistant Acinetobacter infection 
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With the ever increasing isolation of carbapenem resistant strains, the treatment options 
left with the clinician have been severely compromised. This is also due to the fact that 
the isolates tend to be resistant to many of the other commonly prescribed antibiotics. As 
determined by the Infectious Diseases Society of America, A.baumannii is one of the 
“red alert” pathogens that greatly threatens the utility of the currently available 
antibacterial agents(4). The presence of integrons carrying multiple resistance genes on 
them, render many of the available antibiotics useless, in spite of them not being utilized 
in the particular case. 
 
The drugs being advocated for resistant Acinetobacter infections are 
1. Tigecycline- This is a novel glycycline antibiotic, and has a bacteriostatic effect 
on MDR Acinetobacter spp. It is a 9-t- butylglycylamido semi synthetic derivative 
of Minocycline. It also acts by binding to the 30S ribosomal subunit(4). The main 
advantage for this drug is that it evades the resistance mediated by the tet(A) and 
tet(E) determinants which have made the organism completely resistant to the 
action of  tetracycline. Though this drug is being marketed as an alternative 
treatment for MDR Acinetobacter infection, reports of resistance have already 
started to emerge from various parts of the globe. Reports of resistance have come 
in from Germany, Spain, and Israel. In Israel as high as 80% resistance is 
reported.  It also has been found not to provide any benefits when given as 
combination therapy(44). Mechanisms have been elucidated, by which the 
organism has developed resistance to this antibiotic. The organism uses the 
AdeABC efflux pump, to pump out the antibiotic. It has been clearly 
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demonstrated in studies, that the adeB gene is over expressed in isolates, showing 
an increased MIC to Tigecycline. The presence of resistance to the antibiotic is 
already present in the Middle East(45).  The problem is further compounded by 
the lack of standardized guidelines, thus making the interpretation of a zone 
diameter or MIC value not reproducible across testing centers. No break points 
have been set by the CLSI. According to the product information for Tigecycline, 
a fresh medium (not less than 12 hours old) and a paper disc impregnated with 
15µg/ml should be used. Some authors have utilized the break points set for 
Enterobacteriaceae, which is not recommended as the cut off are based on 
extensive studies done on the wild type, infection causing isolates and the drug 
properties in vitro. Comparison of E test with Broth dilution method of MIC has 
not been very satisfactory, with some authors finding excellent concordance 
between the two methods, whereas some have reported a four fold difference(4).  
2. Polymyxins- Belong to a group of polycationic peptides naturally synthesized by 
Bacillus polymyxa, a non actinomycete bacterium. Five chemicals were identified 
of which only two compounds were commercially developed –Polymyxin B and 
Polymyxin E or colistin. They act primarily on gram negative cell wall, leading to 
rapid permeability changes in the cytoplasmic membrane and ultimately cell 
death. These drugs cross the bacterial outer membrane by a self promoted 
pathway by competitive divalent ion displacement by the bulky poly cations, 
which non- covalently cross the bridge adjacent to the polysaccharide 
components. Consequently, the bacterial outer membrane becomes distorted and 
more permeable, permitting increased uptake of the permeabilizing compounds. 
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These drugs till the late 1980’s were the only option for treatment of multidrug 
resistant Ps. aeruginosa infections(46). These drugs were deemed to be too toxic 
for routine use, because of the severe nephrotoxicity and neurotoxicity associated 
with these drugs, with the advent of the cephalosporin class of drugs in the 80’s, 
these drugs were more or less forgotten and their use was restricted to only topical 
use. With the emergence of MDR and Pan drug resistant Acinetobacter infections, 
has led to renewed interest in this class of drugs. It has also been increasingly seen 
that the nephrotoxicity attributed to the administration of these drugs, was in fact 
partly due to the sepsis and the inflammatory response mounted by the patient 
himself. Many trials conducted in vitro have proven the efficacy of these drugs in 
the bactericidal action against these infections. Also clinical trials conducted in 
the United States as well as in centers in Europe, have proven beyond doubt the 
efficacy of these drugs, used in combination therapy especially with rifampicin, 
tobramycin(47). Also in vitro testing, by using Fractional Inhibitory 
Concentration Indices (FICIs), has proven that rifampicin, azithromycin and 
imipenem MICs fell when used in combination with Polymyxin B. FICIs are 
calculated as MIC of drug X (in combination)/ MIC of drug X alone + MIC of 
drug Y(in combination)/MIC of drug Y alone(10, 48). Other in-vitro studies have 
shown a 100% synergistic action against MDR A.baumannii using rifampicin and 
colistin in combination (49, 50). Also a study done has shown 92% synergy 
between colistin and minocycline(51). The better monitoring facilities for renal 
functions have led to the reuse of this drug much more than before. The curative 
rate on treatment with these drugs have been estimated to range from 57 to >80% 
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(4). Studies have proven the use of Colistin in neublized form, for ventilator 
associated pneumonia has proven much more beneficial, without the 
accompanying, nephrotoxicity and neurotoxicity. Only complication noticed was 
broncho spasm. This problem has been solved by using bronchodilators before 
administering the dose of colistin(4). The problem, which is becoming apparent, 
is the super infection with organisms which are inherently resistant to colistin like 
Serratia spp, Proteus spp. The use of intra thecal or intra ventricular colistin for 
nosocomial meningitis caused by Acinetobacter is now documented(4). The CLSI 
has not laid down guidelines for the interpreting the disc diffusion zones(37). This 
is attributed to the fact that the antibiotic is a very large molecule and the 
diffusion into the agar medium is not very satisfactory. It, though has given 
interpretations for MIC’s and studies done have given a good co-relation with disc 
diffusion data(46). Resistance has been documented for this antibiotic as well, 
though the susceptibility for Polymyxin B is 95% and colistin is 96.7%(46). 
Hetero resistance is documented, that is the same sample will have both resistant 
and sensitive strains. The exact mechanism of resistance has not been worked out 
but is attributed to a change in the cell wall permeability, with decreased binding 
to the LPS, or a change in the OMPs(52). 
3. β- lactam and β-lactamase inhibitors- One of the drugs, which holds some 
promise as an alternate for treating Acinetobacter infections is Sulbactam. This is 
a β –lactamase inhibitor and is like clavulanic acid and tazobactam. It is marketed 
in combination with ampicillin or cefeperazone. These β- lactamase inhibitors are 
β-lactam ring containing compounds, which did not have very strong bactericidal 
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effect, when they were discovered. It was also discovered, that these compounds, 
bind to the β-lactamase enzymes, thus keeping the drug safe from the hydrolytic 
action of these enzymes, and enabling the drug to act. The efficacy of these drug 
combinations was assessed and it was found that sulbactam had an intrinsic 
activity against Acinetobacter infections (53); tazobactam had intermediate effect 
whereas clavulanic acid had no activity against them (54). In vitro studies have 
proven conclusively that the, sulbactam component of the combination is the 
effective agent against these infections. This was conclusively proven when the 
MICs of β-lactam alone was compared with that of sulbactam and the 
combination also, and it was seen that there was a reduction of MICs when used 
in combination as compared to the β-lactam drug alone, which was usually 
completely resistant(54). In vivo studies also have proven the usefulness of this 
drug. Studies have documented, an improvement in 95.6% patients started on 
ampicillin-sulbactam combination and 94.4% improvement on Sulbactam only 
therapy(11). Ampicillin-sulbactam is marketed in a ratio of 2:1. Sulbactam now is 
marketed as a solo drug in countries like Germany, Spain, and France. The CLSI 
also has laid down guidelines for the interpretation of ampicillin-sulbactam MICs 
and Disc diffusion testing. A study also proved that the efficacy of a 
cefeperazone-sulbactam combination as compared to imipenem (55). The 
epidemiology of sulbactam sensitivity across the globe is different, with a trend 
towards increased resistance as well. One of the other problematic areas is in the 
treatment of Acinetobacter meningitis, as sulbactam has very poor penetrability 
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into the meninges, thus making this a non viable option for the treatment of 
meningitis (4, 11). 
3.8 Factors affecting outcome in patient’s infected with resistant isolates 
Various factors affect the outcome of patients infected with multidrug and pan drug 
resistant Acinetobacter isolates. Some of the most important factors to be assessed in 
predicting mortality are the co-morbid conditions which the patient has in addition to the 
disease process. These factors include chronic and acute conditions. The chronic 
conditions include diabetes, hypertension, and immunosuppressive conditions like HIV 
etc. The acute conditions include dyselectrolytemia, cardiovascular compromise etc. All 
these factors affect the outcome of the patient. In studies done in evaluate the outcome of 
a disease or interventional strategy it is important to account for these factors as well. 
The acute scoring systems include APACHEII scoring, SOFA scoring. For chronic 
comorbidities the scoring systems are Charlsons scoring index and CDS ( chronic disease 
score). To get rid of these confounding factors in studies many scoring systems have been 
in place to remove the bias in studies. These scores initially were developed for non 
infectious diseases, but of late they have been applied to infectious disease processes as 
well. Charlson scoring index gives differential weight age to different chronic com 
morbid conditions like diabetes with or without renal failure, chronic liver disease, HIV, 
malignancies etc.(ANNEXURE I). A study done to assess the predictive value of this 
score for risk of infection was found to be inadequate (56, 57). 
In patients on artificial ventilation the risk of acquiring a nosocomial infection especially 
pneumonia increases manifold. This is due to the impaired mucociliary action, 
suppression of cough reflex, pooling of secretions. To assess whether a patient has truly 
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developed ventilator associated pneumonia or is at an increased risk for the same a 
scoring system was developed known as the Clinical Pulmonary Infection Score (CPIS). 
The CPIS system has been developed as a score to predict the development of pneumonia 
in intensive care unit patients especially those on ventilators. This scoring system 
developed by Pugin et al in 1991 has proven useful in predicting the development of 
pneumonia in ICU patients. The score has the following components 
• Tracheal secretions 
• Chest X-ray Infiltrates 
• Temperature 
• Leukocyte count 
• PAo2/ Fio2 mmHg 
• Microbiology 
All of the above are given a score of 0 to 2 with a maximum score of 16. It has been 
proven statistically that a score of 6 or >6 at the time of admission and at three days after 
admission to an intensive unit is a strong predictor of VAP (Ventilator Associated 
Pneumonia). This has a sensitivity of 93% and specificity of 100%. The sample to be 
collected for checking the microbiology of the respiratory tract is broncho alveolar lavage 
(BAL)(58, 59). 
This scoring system has been evaluated for prediction of mortality in ICU patients and 
has been compared with APACHE II score and SOFA score. The study revealed that 
CPIS system was not able to predict mortality as compared to APACHEII (60). 
3.9 Trends towards care and treatment of MDR Acinetobacter infections 
With the increased recognition of Acinetobacter as a leading cause of nosocomial 
infections especially in patients who are on mechanical ventilation and in intensive care 
P a g e  | 39 
 
units, leading to increased hospital stay and mortality, the management of these infections 
has become an issue. 
Spread from one patient to another has prompted towards isolation procedures being 
employed, as in segregation of patients, and the restriction of carbapenems as empiric 
therapy agents for ICU admissions. Studies have comprehensively proved the efficacy of 
a sulbactam based therapy, to be as efficacious as an imipenem based therapy, thus 
providing with an alternative antibiotic option, decreasing selection pressure on the 
organism. In addition, surveillance procedures involving the environment and health 
personnel, implementation of Standard Precautions and the search for newer drugs are 
warranted. 
 
 
 
 
 
 
 
 
 
                    
Materials and methods 
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Type of Study-Descriptive 
Materials- A total of 100 isolates of Acinetobacter calcoaceticus-baumannii complex 
were enrolled in this study.  The isolates were from various clinical materials sent to the 
Clinical Microbiology department for bacteriological culture, biochemical identification, 
and antibiotic susceptibility testing. Isolates included in this study were obtained from 
blood, sputum, Endo tracheal aspirate, tracheal aspirate, central lines, cerebrospinal fluid, 
wound swabs, infected tissue.  
Inclusion criteria 
The isolates were collected form patients, who were diagnosed to have nosocomial 
infections defined as infections developing 48 hours after hospital admission. Samples 
collected for a period of 1 year, i.e. samples coming during the time period from, 
December 2006 to December 2007 were included in this study.  As the main objective 
was to detect for OXA-51, using the formula to calculate for prevalence- 
     (Where Z is 95% point of the std. normal distribution and d is the 
precision of the prevalence estimate), the sample size was found to be 73. Hence one 
hundred nosocomial A.baumannii isolates was included in this study. 
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Samples were collected from patients on mechanical ventilation, having central venous 
catheters, indwelling urinary catheters, post surgical patients being subjected to dressing 
or drainage of surgical wounds, including burns. Samples, send from various clinical 
units, were processed according to standard protocol followed in the laboratory(61). All 
samples excluding blood cultures, were inoculated onto 7% sheep blood agar, chocolate 
agar and Mac Conkey agar, streaked by three streak method, and incubated at 37ºC over 
night.  The next day, gram negative bacilli colonies were further characterized by using 
preliminary biochemical screening. The blood cultures in the department are processed in 
semi –automated system Bact/Alert 240.  Based on a colorimetric method, the system 
detects the presence of carbon dioxide produced during the metabolic processes of the 
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organism. Once the carbon dioxide reaches a minimum thresh hold the automation 
machine flags positive. The  bottle is then removed from the machine-Gram stain is done 
from the blood culture supernatant -if there is presence of  gram negative organism, the 
following preliminary biochemical reactions are put up- Mannitol motility medium, 
Triple sugar iron agar medium, Indole production from peptone water, and Citrate 
utilization on Simmons Citrate Medium(61). 
Organisms giving the following reaction, was further taken up in the study- 
• Mannitol motility medium- mannitol not fermented, non motile. 
• Triple sugar iron agar- Alkaline slant/alkaline butt, no gas or hydrogen sulphide 
production, demonstrating the inability of the organism to ferment either of the 
three sugars present- glucose, sucrose, and lactose. Also the organism is unable to 
produce any gas or hydrogen sulphide. 
• Indole production- The absence of a pink ring on adding the indole reagent 
(Ehrlich’s reagent- paramethylaminobenzaldehyde in ethyl alcohol), denotes a 
negative reaction. 
• Citrate utilization- Absence of any blue color denotes absence of increased 
alkalinity, produced as a result of citrate utilization. 
The motility was further confirmed by inoculating the organism in nutrient broth, 
incubating it 37ºC for two hours, and then checking for motility by hanging drop(61). 
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A. PHENOTYPIC CHARACTERIZATION 
Table I: Preliminary Bio-chemical identification  
Bio chemicals  
(Preliminary Screening Media) 
Reaction for Acinetobacter calcoaceticus-
baumannii complex 
Oxidase production Negative(-) 
Mannitol motility medium Not fermented ,Non motile (-,-) 
Triple sugar iron agar Alkaline slant/Alkaline butt(-/-) 
Indole production Negative(-) 
Citrate utilization Negative(-) 
1. Biochemical identification of Acb complex 
All Oxidase negative non motile non fermenting gram negative bacilli were 
biochemically characterized, to identify the strains of A. calcoaceticus-baumannii 
complex(7). The following biochemical reactions were set up.  
Table II: Biochemicals used to identify Acb Complex 
Reactions A.calocaceticus-baumannii complex(expected result)(7) 
Oxidase Negative 
Motility Negative 
Gram stain Gram negative cocco bacilli or bacilli 
OF Dextrose Oxidative utilization only 
Nitrate reduction Negative 
Malonate utilization Positive 
Arginine utilization Positive 
All the isolates were biochemically characterized using the following bio chemicals – 
oxidase reaction of the organism was determined by using a Whatmann filter paper No. 2  
soaked in Oxidase reagent(1% aqueous solution of tetra methyl-para-phenylene diamine 
dihydrochloride), Hugh Leifson  medium for determination of oxidative utilization of 
glucose, malonate broth for determination of malonate utilization, Moeller’s 
decarboxylase medium for determination of arginine dihydrolase production ,and 
potassium nitrate broth for determination of nitrate reduction(7).  
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B. Anti microbial profile 
2a. Disc diffusion method 
Antibiotic sensitivity was assessed for all the strains, by disc diffusion method, using the 
modified Kirby –Bauer method(61). Medium used was Mueller-Hinton agar (Obtained 
from Difco) poured in an 85 mm plastic plate. The organism was sub cultured on sheep 
blood agar, to obtain it in pure culture. Three to four colonies were suspended, in nutrient 
broth and incubated for two hours at 37ºC, so as to get the organism in the logarithmic 
phase. The density of the suspension was standardized with nutrient broth, visually 
equivalent to the Barium Sulphate standard, 0.5 McFarland units. Within, fifteen minutes 
of preparation of the suspension, a sterile cotton-wool swab was dipped into the 
suspension and the surplus removed by rotating the swab against the side of the test tube. 
With this swab, the agar plate was inoculated by even stroking of the swab over the entire 
surface of the plate in three directions so as to obtain a lawn culture. After brief drying, 
the antibiotic disc was placed, 6 on each plate(61). With each batch of tests, a control for 
each antibiotic was also set up. The control strains were obtained from American Type 
Culture Collection (ATCC). The control strains were included as per the CLSI guidelines. 
 
 
 
 
 
 
Table III: Source and control strains of Antimicrobial agents used 
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Antibiotic Source Control strain used(37) 
Cefotaxime(30µg) Sigma Ps.aeruginosa ATCC 27853  
Ceftazidime(30µg) Sigma Ps.aeruginosa ATCC 27853  
Cefepime(30µg) Becton Dickinson Ps.aeruginosa ATCC 27853  
Amikacin(30µg) Hi Media Ps.aeruginosa ATCC 27853  
Gentamicin(10µg) Sigma Ps.aeruginosa ATCC 27853  
Netilmicin (30µg) United Biotech Ps.aeruginosa ATCC 27853  
Levofloxacin(5µg) Cipla Ps.aeruginosa ATCC 27853  
Ciprofloxacin(5µg) Sigma Ps.aeruginosa ATCC 27853  
Chloramphenicol (30µg) Oxoid S.aureus ATCC 25923  
Ticarcillin/clavulanicacid(75/10µg) Becton Dickinson Ps.aeruginosa ATCC 27853  
Piperacillin/tazobactam (100/10µg) Becton Dickinson Ps.aeruginosa ATCC 27853  
Cefeperazone/sulbactam (75/10µg) Becton Dickinson Ps.aeruginosa ATCC 27853  
Trimethoprim /Sulfamethoxazole 
(1.25/23.75µg) Hi Media S.aureus ATCC 25923  
Tigecycline( 15µg) Oxoid Ps.aeruginosa ATCC 27853  
Colistin(10µg ) Hi Media Ps.aeruginosa ATCC 27853  
Polymyxin B (300U) Sigma Ps.aeruginosa ATCC 27853  
Imipenem(10µg ) Ranbaxy Ps.aeruginosa ATCC 27853  
Meropenem(10µg ) Astra-Zeneca Ps.aeruginosa ATCC 27853  
Interpretations were made using the Clinical and Laboratory Standards Institute, USA 
guidelines (January 2008, M100-S18- Volume 28 No.1, Table 3, Page 78/79)(37) and 
reference was used for Polymyxin B Disc diffusion as no CLSI guidelines exist for the 
same(46). 
 
 
For Tigecycline the guidelines laid down by F.D.A. were used. 
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(http://www.wyeth.com/content/showlabeling.asp?id=474). 
Tigecycline DD Control- Escherichia.coli ATCC 25922 (22-28mm) 
 Susceptible (mm) Intermediate (mm) Resistant (mm) 
For Acinetobacter >19 15-18 <14 
 
Using the CLSI guidelines, 80 isolates which were resistant to imipenem and meropenem 
and 20 susceptible isolates were included.   The cut of for disc diffusion, as given by 
CLSI is-Imipenem (10µg-<13mm to >15mm{R-S}, and Meropenem 10µg-<13mm to 
>15mm{R to S})(37)..  
2b. Minimum Inhibitory Concentration Estimation 
The Minimum Inhibitory concentration for Polymyxin B was estimated by agar dilution 
method for the 80 imipenem, meropenem resistant strains(61). The medium used was 
Mueller Hinton agar with serial dilutions of the antibiotic, 18-20 ml of the medium was 
prepared in test tubes and allowed to cool in 50ºC water bath. Serial dilutions of the 
antibiotic Polymyxin B were made in sterile saline. Doubling dilutions were made by 
weighing 1 mg of pure substance of Polymyxin B, dissolving it in 5.64 ml of sterile saline 
and so as to obtain a concentration of 640µg/ml, and diluting it serially so as to obtain a 
dilution of 0.31µg/ml in the last tube. The diluted antibiotic was added to the cooled 
medium, in a ratio of 2 ml of the Polymyxin B solution with 18 ml of the agar so as to 
obtain a maximum concentration of 64µg/ml and a least concentration of 0.031µg/ml. 
After adding the Polymyxin B solution, the agar was mixed well, and poured into the 
Petri dish. After allowing the medium to settle and solidify, the plates were dried. One 
control plate containing only the agar without the antibiotic solution was also made.  The 
inoculum was standardized by adjusting the suspension made in nutrient broth, to 0.5 Mc 
Farland units, and then taking 0.001 ml of the broth and diluting in 5 ml of saline.  The 
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control strain used was Ps.aeruginosa ATCC 27853. The test inoculum was spot 
inoculated with the help of a platinum loop, so as to deliver 0.001 ml of the inoculum. 
The plates were incubated at 37ºC for 18 hours, and the reading was taken as presence of 
growth or absence of growth at the spot of inoculation, in the serially diluted antibiotic 
plates. Interpretations were based on the CLSI guidelines, January 2008, volume 28, no.1, 
M7-A7 page number 143, and page No.104. For obtaining the MIC for sulbactam, a 
similar procedure was carried out so as to obtain a highest dilution of 32µg/ml and a 
lowest concentration of 0.5µg/ml on the plate. Control used was Esc.coli ATCC 25922. 
The interpretations were made as per CLSI 2008 guidelines(37). 
For Polymyxin B 
 Sensitive (µg/mL) 
Resistant 
(µg/mL) 
Pseudomonas aeruginosa ATCC 27853 <0.25 >2 
Acinetobacter calcoaceticus-baumannii complex <2 >4 
For Sulbactam 
 Sensitive (µg/mL) 
Intermediate 
(µg/mL) 
Resistant 
(µg/mL) 
Escherichia.coli ATCC 25922 <1 - >4 
Acinetobacter calcoaceticus-baumannii 
complex <4 8 >16 
 
 
 
 
 
 
3. Molecular characterization of strains. 
P a g e  | 48 
 
The presence of OXA-51 and OXA-23 was detected in using modified, Multiplex 
Polymerase Chain Reaction protocol reported by Turton et al. (26).  
DNA extraction- The organism was grown in pure, on sheep blood agar, at 37ºC 
overnight. Three colonies of the organism were suspended in 100µl of sterile saline and 
were kept in water bath at 100ºC for half an hour. Following this the suspension was 
centrifuged at 6,000 rotations per minute for 2 minutes, and 3µl of the supernatant was 
used as DNA template. 
Table IV: Molecular reagents used and their source  
 Company 
10XPCR buffer Fermentas Life Sciences, USA 
1.5 nM MgCl2 Fermentas Life Sciences, USA 
1.5 Taq  DNA Polymerase Fermentas Life Sciences, USA 
Deoxy Nucleotide Tri Phosphate(200µM) Fermentas Life Sciences, USA 
Primer OXA-23 Forward(12.5 pmol) Sigma Aldrich Chemicals Pvt. Ltd, Bangalore 
Primer OXA-23 Reverse(12.5 pmol) Sigma Aldrich Chemicals Pvt. Ltd, Bangalore 
Primer OXA-51 Forward(12.5 pmol) Sigma Aldrich Chemicals Pvt. Ltd, Bangalore 
Primer OXA-51 Reverse(12.5 pmol) Sigma Aldrich Chemicals Pvt. Ltd, Bangalore 
Sterile water for injection Nirilife, Gujarat. 
 
The primers for the Polymerase chain reaction were obtained from Sigma Aldrich 
Chemicals Pvt. Ltd, Bangalore. The oligonucleotides were provided as a desalted base 
and, the primers were reconstituted as per the manufacturer’s instructions in 0.5X TE 
buffer. As per manufacturer’s instructions, stocks were stored at -20ºC and aliquots were 
stored at 4ºC. 
 
The Primer sequences were:  
Oxacillinase 23(26) 
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Target Base pair size Author 
Year of 
publication  OXA-23 blaOXA-23like 501 Turton et al August 2006 
 
[F]-5´-GAT GTG TCA TAG TAT TCG TCG T-3´ 
[R]-5´-TCA CAA CAA CTA AAA GCA CTG T-3’ 
 
Oxacillinase 51(26) 
Target Base pair size Author 
Year of 
publication  OXA-51 blaOXA-51like 353 Turton et al August 2006 
 
[F]-5'-TAA TGC TTT GAT CGG CCT TG-3' 
[R]-5'-TGG ATT GCA CTT CAT CTT GG-3' 
 
 
Table V:  Volume of each reagent used for one PCR reaction 
 The total reaction volume was 25µl. Each component of the Master Mix was as follows. 
 In micro liters 
10XPCR buffer 2.5 
1.5 nM MgCl2 1.5 
1.5 Taq  DNA Polymerase 0.3 
Deoxy Nucleotide Tri Phosphate(200µM) 0.5 
Primer OXA-23 Forward(12.5 pmol) 0.25 
Primer OXA-23 Reverse(12.5 pmol) 0.25 
Primer OXA-51 Forward(12.5 pmol) 0.25 
Primer OXA-51 Reverse(12.5 pmol) 0.25 
Sterile water 15.7 
Total 22 
 
To this, 3µl of extracted DNA was added. 
The Multiplex PCR (26), cycling settings were as follows 
1. Initial denaturation was done at 94ºC for 3 minutes followed by 
2. 35 cycles of 
Denaturation at 94ºC for 45 seconds 
Annealing at 57ºC for 45 seconds 
3. Extension at 72ºC for 1 minute followed by 
4. Extension maintenance at 72ºC for 5 minutes. 
Detection of the specific amplicons was done by performing electrophoresis on 2% 
Agarose gel (Obtained from Sigma). The gel was prepared by adding 2 mg agarose in 
P a g e  | 50 
 
100 ml of 1XTBE buffer, heating it, so as to melt it and then pouring in gel tray and 
allowing it to set. Blank reaction was also run so as to check for the purity of the reaction. 
Control strains (Courtesy: David W. Wareham, Centre for Infectious Disease, Institute of 
Cell and Molecular Science, Barts and The London, Queen Mary’s School of Medicine 
and Dentistry, London, UK) were included in every run.  The controls were- one strain of 
Acinetobacter baumannii-calcoaceticus complex positive for OXA-51 only, one control 
strain positive for both OXA-23 and OXA-51 and the third strain negative for both OXA-
51, OXA-23. 
 
 
 
 Also a, molecular weight ladder, a 50 base pair DNA ladder (O’ Range Ruler, obtained 
from Fermentas Life Sciences, USA) was included in the gel electrophoresis so as to 
detect the base pair weight of the amplicons obtained.    The electrophoresis was run at 
120V for one hour, in 0.5XTBE buffer. 
This gel was then stained in 0.5% Ethidium bromide (obtained from Sigma Aldrich) so as 
to stain the DNA products which were then visualized using the Universal Hood II gel 
documentation machine form BIO RAD laboratories. The molecular weight of the 
product expected was, for OXA-51- 353 bp and for OXA-23- 501 bp. 
Eighteen randomly selected strains were assessed fro the presence of other genes 
encoding for resistance (Courtesy: David W. Wareham, Centre for Infectious Disease, 
Institute of Cell and Molecular Science, Barts and The London, Queen Mary’s School of 
Medicine and Dentistry, London, UK).  
Control strains Bands expected 
Ab11 OXA-23 and OXA-51 positive 
Ab14 OXA-51 only 
Ab36 No band 
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Isolates were tested for the following genes: 
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1.ESBLs 
• TEM, 
• SHV-like, 
• CTX-M3 like, 
• CTX-M14 like 
• PER 
• VEB 
2.AmpC 
• MOX-like, 
• DHA-like 
• ACC-like 
• EBC-like 
3.Carbapenemases  
• Class D-OXA 58and OXA-24  
• Class A-KPC 
• Class B- IMP, GIM, VIM, 
SPM,SIM 
4.Quinolone resistance determinants  
• qnrA, qnrB, qnrS 
5. Integrons  
• Class I,II,III 
P a g e  | 53 
 
• FOX-like  
 
B. Clinical correlation 
4a. Clinical Pulmonary Infection Score (CPIS) 
Also the clinical pulmonary score was calculated for the patients suffering nosocomial 
pneumonia, using the Clinical Pulmonary Infection Score.  
Table VI: CPIS (58)  
CPIS POINTS 0 1 2 
Tracheal Secretions Rare Abundant Abundant +purulent 
Chest X-ray infiltrates No infiltrate Diffused Localized 
Temperature >97.4 and <101.2 >101.2 and<102.2 >102.2 or <96.8 
Leukocytes/mm3 >4000and<11000 <4000or>11000 <4000or>11000+band 
PAo2/ Fio2,mmHg >240or ARDS - <240 or no ARDS 
Microbiology Negative - Positive 
Total score= 
 
4b. Charlson Chronic Co-Morbidity Index                                                 
The chronic co morbidity scoring was done using the Charlson Co-morbidity Index. Co-
morbid conditions such as diabetes and vascular disease are among the many factors that 
contribute to the risk of infection with antibiotic-resistant bacteria. The co-morbidity index 
developed by Charlson et al. is a validated method of classifying co-morbidity to predict 
short- and long-term mortality. It replaces direct measures of the severity of an illness, which 
require a prospective data collection. The Charlson index assigns weights for a number of 
major conditions present among secondary diagnoses. The index score is the total of assigned 
weights, and represents a measure of the burden of co-morbid disease. It has been 
successfully used as a risk-adjustment approach conjunction with laboratory and clinical data. 
The Charlson Co-morbidity Index was originally designed as a measure of the risk of 1-year 
mortality attributable to co-morbidity in a longitudinal study of general hospitalized patients. 
This scoring system though not developed for assessing infectious pathologies has been 
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successfully adapted to the same and studies have shown that it can be used as a predictor of 
infection with antibiotic resistant organisms.  (ANNEXURE I). 
4c. Outcome in patient infected with nosocomial A.baumannii resistant to 
Carbapenems and Tigecycline. 
An attempt was made to correlate the clinical outcome of patient infected with a carbapenem 
resistant and Tigecycline resistant isolate. A 2X2 table was constructed and the p value was 
calculated, to assess if infection with the resistant isolate significantly influenced the 
mortality rate in patients. 
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RESULTS 
 
A. Materials – One hundred clinical isolates of Acinetobacter baumannii obtained 
from patients suffering from nosocomial infections were included in this study.  
 Fig.1: Age distribution of the patients with nosocomial A.baumannii 
infection 
 
The bar diagram shows the age wise distribution of the patients,  whose isolates were 
included in the study.  Majority of the isolates were in the 50-60 year age group, and the Inter 
Quartile Range (IQR: 31 yrs ) , with the youngest being aged 12 days to the oldest being 77 
years. 
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Fig.2: Sex Distribution of the patients with A.baumannii nosocomial 
infection  
The pie diagram depicts the sex distribution of the 
isolates investigated in the study, 68 of which 
were isolated from male patients and the rest from 
female patients. 
Fig.3: Nosocomial A.baumannii isolates included from various clinical 
samples. 
 
The bar diagram shows the various clinical samples from which the isolates were included in 
the study. Majority of the specimens were  received from patients on ventilators and this 
included Endotracheal aspirate ( patients with an endotracheal tube in situ) and tracheal 
aspirate ( patients with a tracheostomy). 
Fig.4: Nosocomial A. baumannii from various systemic/local infections.  
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Figure 4 shows the number of 
patients  with nosocomial infections, 
which were grouped according to the 
clincial diagnosis. 
 
 
Fig.5: Number of carbapenem 
resistant and susceptible 
nosocomial A.baumannii 
isolates studied(n=100). 
 
The diagram depicts the number of 
strains that were resistant (n=80) 
and susceptible (n=20) in this 
study.  
 
 
B. Biochemical identification. 
All the clinical isolates were characterized phenotypically and identified as A.baumannii. The 
preliminary screening was based on the following bio chemical profile  
• Non motile,  
• Oxidase negative   
• Triple sugar iron showing alkaline slant with alkaline butt with no gas production. 
• Indole negative.  
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These were further characterized by extended biochemical tests as follows 
• Oxidative utilization of glucose,  
• Nitrate reduction,  
• Arginine dihydrolysis  
• Malonate utilization. 
Six isolates of the one hundred isolates tested,  had variable biochemical reactions. Three 
isolates were negative for Arginine dihydrolysis and three were negative for Malonate 
utilization(7).These variable bio chemical reactions are expected for A.baumannii.   
C. Anti microbial Susceptibility profile. 
C.1 By Disc Diffusion test 
Table I: Antimicrobial susceptibility profile of nosocomial A.baumannii 
isolates. 
   
R= Resistant, S= Susceptible, I= Intermediate 
susceptible  
 
CTX-cefotaxime, LEVO- levofloxacin, SXT- 
Sulfamethaxzole+ Trimethoprim, 
CZD-ceftazidime, CIPRO- Ciprofloxacin, CHLO- 
Chloramphenicol,  
CPI- Cefipime, CEF+SULB- 
cefaperazone+sulbactam, PB300- Polymyxin B 
 GENT- Gentamicin, Tim-Ticarcillin+Clavulanic acid 
,Colistin  
AK-Amikacin, P/T- Piperacilin+ Tazobacatm, TIG-
Tigecycline 
 
 
 
 
 
 
n=100 R S I 
CTX 100 0 0 
CZD 100 0 0 
CPI 98 2 0 
GENT 85 15 0 
AK 84 16 0 
LEVO 80 19 1 
CIPRO 85 15 0 
CEF+SULB 74 18 8 
TIM 99 1 0 
P/T 99 1 0 
SXT 76 24 0 
CHLO 89 11 0 
TIG 73 20 7 
COLISITN 4 96 0 
PB300 4 96 0 
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Fig7:  Antimicrobial  profile of nosocomial A.baumannii  ioslates.( n = 100) 
 
Figure 7 depicts the antimicrobial  profile for as determined by the disc diffusion test, using 
the modified Kirby-Bauer method. The interpretations were done using the CLSI January, 
2008 guidelines  and published references for PB 300, Colistin and Tigecycline. There was 
100% resistance detected to CTX,CZD and very high levels of resistance to β-lactam+β-
lactamase inhibitor combination. Also the level of resistance was more than 80% to the 
fluoroquinolone and amino glycoside groups. The most effective drugs seem to be the 
Polymyxins ( PB300 and Colistin) which showed  96% susceptibility. 
 
 
 
 
 
Fig.8:  Tigecycline susceptibility among nosocomial A.baumannii resistant 
to carbapenems.(n = 80) 
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Tigecycline is advocated as a alternate 
drug for treatment of carbapenem resistant 
isolates. Disc diffusion carried out showed 
that all of the resistant strains,none were 
susceptible to Tigecycline ( 9% showing 
intermediate susecptibility to Tigecycline). 
C.2 Minimum inhibitory concentration (MIC) 
Fig.9: Polymyxin B susceptibility pattern of nosocomial A.baumannii 
resistant to carbapenems 
determined by Agar dilution 
method(n = 80). 
The MIC was determined for 
Polymyxin B by the agar dilution 
method and interpretations were made 
using the CLSI 2008 guidelines. The 
figure depicts 95% of the isolates were 
inhibited by  Polymyxin B, making this 
an effective alternative therapeutic agent. 
Table II: MIC values obtained for Polymyxin B nosocomial A.baumannii 
resistant to carbapenems. 
MIC dilutions for 
Polymyxin B (µg/ml) 64 32 16 8 4 2 1 0.5 0.25 0.125 0.0625
A.baumannii 
(n=80)   3 1  5 61 15    
Ps.aeruginosa ATCC 
27853       1     
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The minimum inhibitory concentration was determined for Polymyxin B was determined 
using agar dilution technique. This revealed the MIC’s of majority of the susceptible isolates 
to be around 1µg/ml. The control used Ps.aeruginosa ATCC 27853, which was satisfactory. 
Four isolates were found to be resistant to Polymyxin B.   
Table III: Details of nosocomial A.baumannii resistant to Polymyxin B. 
Sample I.D. Source MIC value (µg/ml) Patient outcome 
SP2176 Endotracheal Aspirate 16 Cured 
SP1400 Endotracheal Aspirate 16 Expired 
SP4151 Endotracheal Aspirate 16 Expired 
SP4051 Endotracheal Aspirate 8 Expired 
There were however four isolates with an MIC in the resistant range. Three of these had an 
MIC of 16 whereas one had an MIC of 8. Three of these pateints died. 
 
 
 
 
 
Fig.10: Sulbactam susceptibility pattern of nosocomial  A.baumannii 
resistant to 
carbapenems.  
MIC for Sulbactam 
was performed by the 
agar dilution method 
and interpreted by 
using the CLSI 
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guidelines, showed that only 11% of the isolates were being inhibited by Sulbactam. 
 
Table IV: Sulbactam MIC values for nosocomial A.baumannii resistant to 
carbapenems. 
 
Table four depicts the Sulbactam MIC values obtained for the isolates tested.  Sixty nine of 
these isolates had an MIC in the resistant range and majority of the isolates were found to be 
inhibited only at a drug concentration of 16µg/ml. Clearly this shows that the drug is not 
effective in the carbapenem resistant isolates in this study.   
 
 
D. Molecular determination of resistance.  
 A  modified multiplex PCR was standardized  using published protocol( Turton et al 2006). 
The amount of Magnesium chloride added was increased from 1µl to 1.5µl per 25µl reaction 
as compared to the published protocol. 
MIC 
dilutions for 
Sulbactam 
(µg/ml) 
256 128 64 32 16 8 4 2 1 0.5 0.25 0.125 0.0625 0.03125
A.baumannii 
(n=80)    10 58 2 1 3 4      
Esc.coli 
ATCC 25922        1       
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Fig: 11 Ethidium bromide stained gel showing bands for OXA-51 and 
OXA-23. 
 
This picture depicts the standard  multiplex PCR including controls provided. Lane 3,4,5 are 
the controls included and the rest of the lanes are a clinical isolates of A.baumannii. 
Fig.12: OXA-51 in nosocomial A.baumannii isolates.  
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Of the tested 80  carbapenem resistant isolates, 95% of them were positive for the gene 
encoding for OXA-51. Of the twenty susceptible isolates tested, 80% were positive for the 
gene. This favours the hypothesis that OXA-51 may be a molecular marker for identification 
of A.baumannii.  
Fig.13: OXA-23 in nosocomial A.baumannii isolates.  
 
Figure 13 shows the number of isolates which were positive for the gene encoding for OXA-
23 enzyme. It was found to be positive in 58 of the tested 80 carbapenem resistant isolates. 
The susceptible strains were all negative for OXA-23. 
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TableV: Comparative table showing the  nosocomial A.baumannii isolates 
positve for OXA-51 and OXA-23 
 
OXA-51 
 
 
OXA-23 
   Carbapenem 
Susceptible(n=20) 
Carbapenem 
Resistant(n=80)
Carbapenem 
Susceptible(n=20)
Carbapenem 
Resistant(n=80)
Positive 16 76 0 58 
Negative 4 4 20 22 
 
Table V shows the number of  A.baumannii isolates which were positive for OXA-51 and 
OXA-23. It shows the presence of OXA-51 in both susceptible and resistant strains. Thus the 
OXA-51 may be used a molecular marker. The number of carbapenem resistant A.baumannii 
isolates positive for OXA-23 is 58. None of the susceptible isolates were positive for OXA-
23. Thus OXA-23 seems to play a major role in determination of carbapenem resistance. The 
carbapenem resistant isolates negative for OXA-23, could have become resistant due to other 
mechansims or even with only OXA-51. 
 
 
 
 
 
Table VI:  The other resistance determinants identified in the randomly 
selected eighteen isolates.  
P a g e  | 66 
 
 
 
 
 
 
 
 
 
 
 
Other genes tested  
          ESBL 
TEM 4 
SHV-like 0 
CTX-M3 like 0 
CTX-M14 Like 0 
PER 1 
VEB 0 
Transmissible Amp-C 
MOX 0 
CIT-like 0 
DHA-like 0 
ACC-like 0 
EBC-like 0 
FOX-like 0 
Class D carbapenemases 
OXA-58 0 
OXA-24 0 
Class A carbapenemases 
KPC 0 
Class B carbapenemases 
IMP 0 
VIM 0 
GIM 0 
SPM 0 
SIM 0 
Quinolone resistance 
qnrA 0 
qnrB 0 
qnrS 0 
Integrons 
Class I 11 
Class II 0 
Class III 0 
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Table six outlines the various molecular determinants of resistance which were looked for 
in the randomly selected carbapenem resistant A.baumannii isolates. All the isolates were 
negative for other classes of carbapenemases. Of interest is the fact that eleven of the 
eighteen isolates were positive for class I integrons. These Class I integrons encode 
resistance for various classes of anti microbial agents at the same time and explain the 
resistance of tested isolates to so many classes of anti microbial agents. .( Courtesy: 
David W. Wareham,  UK). 
Fig.14: Number  among the randomly chosen A.baumannii isolates 
found to carry other 
genes encoding for 
resistance ( n =18).  
Figure 14 shows the number of 
isolates which were identified 
to be carrying the genes tested 
for. One of the isolate was 
positive for PER gene,  four 
positive for the TEM gene and 
eleven of the isolates were 
positive for Class I Integron. 
Rest of the genes tested for 
were negative in all the 18 isolates.  
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Fig.15: Outcome of the patients infected with A.baumannii isolates. 
 
Of the number of patients infected with 
a carbapenem resistant isolate (n=80), 57 of them expired. Of the number of pateints 
infected with carbapenem susceptible isolate (n=20), eight died. 
Table VII: Comparative table showing outcome of nosocomial 
A.baumannii infected patients with carbapenem resistant/susceptible 
strains. 
Carbapenem AST Mortality No mortality 
Resistant 
(n=80) 57 23 
Susceptible 
(n=20) 8 12 
p value=0.018 significant. 
The above table compares, the mortality in patients infected with a carbapenem resistant 
strain as compared to infected with a susceptible strain. The calculated p value is highly 
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significant and shows that the infection with a carbapenem resistant strain predisposes to 
a higher mortality. 
Table VIII: Comparative table showing outcome of carbapenem 
resistant nosocomial A.baumannii infected patients with Tigecycline 
resistant/susceptible strains. 
Tigecycline AST Mortality No mortality 
Resistant 
(n=73) 41 32 
Moderately susceptible 
(n=7) 6 1 
p value= 0.23 
The outcome of patients infected with  tigecycline resistant A.baumannii was assessed. 
Infection with a tigecycline resistant strain did not signifcantly effect the outcome of the 
patient. 
Table IX:Comparative table showing outcome of nosocomial 
A.baumannii infected patients with Pan drug resistant strains. 
Resistance Mortality No mortality 
Pan drug resistant 
(n=57) 37 20 
Not pan drug resistant 
(n=43) 24 21 
p value=0.36 not significant 
The above table compares the mortality in patients infected with a pan drug resistant 
isolate(isolate resistant to all except Polymyxins) as compared to infection with a non-pan 
drug resistant isolate. No significant increase in the mortality was observed in patients 
who were infected with pan drug resistant A.baumannii isolates. 
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Table X: CPIS (Clinical Pulmonary Infection Score)  
Score Expired Cured Total 
0 to 6 2 8 10 
7 to 9 5 6 11 
10 to 12 36 21 57 
     
The clinical pulmonary infection score was calculated for patients suffering from 
nosocomial pneumonia(n=78). As per recommendations assuming 6 as cut off for the 
clinical diagnosis of VAP, we found that there was an increase in death rate with an 
increase in CPIS. 
Fig.16: Charlson Comorbidity Scoring index 
 
 
 
 
 
 
 
 
 
 
 
 
*the chronic co-morbid entities list is given as annexure I. 
CPIS Mortality No mortality 
<6 2 8 
>6 41 27 
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It was found that there was no significant association between mortality and any chronic 
comorbid condition. 
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                                                                    DISCUSSION 
Discussion 
Acinetobacter calcoaceticus-baumannii complex has emerged as the leading cause of 
mortality and morbidity in hospital acquired infections. The organism is mainly isolated 
from the respiratory tract, in patients on artificial ventilation.  A study published from 
CMC Vellore, has shown an incidence of 14.2% for carbapenem resistant Acinetobacter 
spp. isolated from endo tracheal aspirates (8). A study done in JIPMER, Pondicherry has 
shown an incidence of 48.8% of Acinetobacter spp. (16).  Acinetobacter infections most 
frequently involve the respiratory tract of intubated patients and Acinetobacter 
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pneumonia has been more common in critically ill patients in Asian (range 4–44%) and 
European (0–35%) hospitals than in United States hospitals (6–11%) (20)). 78% of 
isolates included in this study had come from patients suffering from pneumonia. 
The organism has become increasingly difficult to treat with the increasing number of 
isolates being resistant to many of the different class of drugs. The definition of 
multidrug and pan drug resistant has varied in various studies.  Various studies done in 
India have failed to clearly define the definition used for classifying an isolate as being 
multidrug or pan drug resistant ((62, 63). Some authors have termed isolates as being pan 
drug resistant without testing for Polymyxins. Kuo et al. (2003) from Taiwan defined 
PDR as resistance to all antibiotics commercially available (ceftazidime, ciprofloxacin, 
cefepime, aztreonam, ciprofloxacin, piperacillin–tazobactam, ticarcillin–clavulanate, 
ofloxacin, amikacin, imipenem and meropenem). No testing was done for colistin or 
ampicillin–sulbactam (64)Wang et al. (2003) from Taiwan defined PDR as resistance to 
all currently available antimicrobials (including carbapenems), except colistin and 
Polymyxin B(65). PDR in this study was defined as isolates resistant to all antibiotics 
except colistin. The same problem plagues the definition of Multi drug resistant 
Acinetobacter. Ruiz et al. (2003) from Spain have described isolates resistant to at least 
amikacin, amoxycillin–clavulanic acid, ampicillin, ceftazidime, and 
chloramphenicol(66). Smolyakov et al. (2003) from Israel described isolates resistant to 
all antibiotics tested routinely but susceptible only to ampicillin–sulbactam and 
colistin(67). Urban et al. (2003) from USA have described isolates resistant to cefepime, 
ceftazidime, or imipenem, or sensitive only to polymyxins and sulbactam(68). In this 
study MDR was defined as those isolates showing resistance to more than two of the 
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following classes of antibiotics (Anti pseudomonal cephalosporins (ceftazidime or 
cefepime), antipseudomonal carbapenems (imipenem or meropenem), ampicillin-
sulbactam, fluoroquinolones (ciprofloxacin or levofloxacin), and aminoglycosides 
(gentamicin, tobramycin, or amikacin). 
The carbapenem resistant A.baumannii isolates were also tested for their susceptibility 
towards Tigecycline by the disc diffusion method. Also the susceptibility to Polymyxin B 
and Sulbactam was assessed performing MIC using the agar dilution method.  Of the 
tested resistant isolates none were completely susceptible to Tigecycline. Only 9% of the 
tested isolates were intermediately susceptible to the drug (n=80). The resistance to 
Tigecycline has varied in different studies. This is because there are no universal 
prescribed guidelines for the in vitro testing for Tigecycline. No studies have been 
performed in India. Souli et al (69), have shown 100% susceptibility to Tigecycline 
(n=100). 26% isolates from a study in Argentina have been reported to be resistant(70). A 
study published from Israel has shown a resistance rate of 66% with 12% being 
intermediate susceptible (n=82)(71) . Interpreting the data generated from this study, it 
becomes clear that there is a definite difference in the susceptibility pattern of 
Acinetobacter across different geographical areas. This can partly be explained based on 
the fact that the cut of guidelines given by BSAC is different as compared to FDA 
guidelines. A better picture would emerge if there were uniform guidelines developed for 
the interpretation of Tigecycline susceptibility.  Another potential point of error is the 
content of manganese present in the Mueller-Hinton agar used for sensitivity testing, with 
a higher manganese content giving more isolates as resistant as compared to a lesser 
amount of manganese(72).  
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 Various studies have proven the efficacy of Sulbactam as an alternate drug. Studies done 
in France and Spain (n=47 patients) (53) have proven the efficacy of this drug as mono 
therapy to treat carbapenem resistant Acinetobacter (11). This agent is not available as a 
pure substance in India. The drug is available as combination with ampicillin and 
cefeperazone. Various studies done in India have revealed a resistance range of 5.3% to 
48.2% to these combination drugs (62, 73). A study done in 2003 has shown a resistance 
rate of 54.3% in Turkey.(n=121)(74). A study done in Chile has shown an increase over 
time in the resistance rates towards Sulbactam, from 30.8%in 1990-1992 to 51.7% in 
1997-1998(75). Another study has shown a resistance rate of 68.2% (9). Surprisingly of 
the isolates tested for susceptibility to Sulbactam, only 11% were susceptible and another 
3% were intermediately susceptible. 
Of the eighty strains subjected to susceptibility testing for Polymyxin B in this study, 
95% were found to be susceptible.  This is in accordance to the various studies published 
having proven. Polymyxins have been proven to be an effective therapeutic agent against 
carbapenem resistant Acinetobacter spp. No studies have been performed in India to 
specifically look at the in vitro activity of polymyxins against carbapenem resistant 
Acinetobacter spp.   Studies done in various parts of the world have shown 95.8% to 
100% of the isolates to be susceptible (n=48, Azap Kurt et al 2006, n=66, Dizbay 
2008)(9, 76). Use of polymyxins has also gained popularity due to the better monitoring 
facilities of renal functions and dialysis.   
 The presence of four isolates which were resistant to Polymyxin B is of concern. Though 
no reports have been published from India regarding resistance to Polymyxins, but 
reports of colistin resistance has emerged from Australia(77). Report of Polymyxin B 
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resistance ranging from 2.1% to 88.9% has been published from a study in Korea.(78). 
One of the potential problems with testing for Polymyxin B susceptibility is there are no 
standard guidelines for interpreting disc diffusion values. CLSI does not give guidelines 
for the same. Values used in this study are from the work done by Gales et al( (46). This 
is because the Polymyxin molecule is of very large molecular weight and does not diffuse 
uniformly in the agar medium and hence the standard recommendations is to report an 
isolate as being resistant only after performing an MIC on the suspect isolate.       
The gold standard for identification of this organism is DNA-DNA hybridization as 
described by Bouvet et al. This is an elaborate and cumbersome procedure and is done 
only in select reference laboratories. The bio chemical identification system cannot 
differentiate between A. baumannii, A.calcoaceticus, Acinetobacter genomospecies 3 and 
Acinetobacter genomospecies 13TU. This is the reason, that for conventional 
identification systems, Acinetobacter is reported as A. calcoaceticus-baumannii complex 
or sacchrolytic Acinetobacter.  The search for alternate identification markers has lead to 
the identification of OXA-51 as a molecular marker for identification of Acinetobacter 
baumannii. A study done by Turton et al in 2006 had shown the presence of this gene 
only in A.baumannii (n=141). The isolates were also further confirmed by using DNA-
DNA hybridization technique. The gene was absent in A.calcoaceticus, A.lwoffii.(12). A 
study done in Turkey showed 77.8% of the isolates to be carrying the OXA-51(n=72) 
(79). Confirmation of isolates was not done in this study.  Another study done in Iran 
detected the presence of OXA-51 in all the isolates tested (n=108) (80). No such studies 
have been carried out in India till date. Of the isolates tested in this study (n=100), 92 
showed the presence of OXA-51. This shows the presence of OXA-51 in a large number 
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of our isolates.  The rest of the eight isolates which does not show the presence of OXA-
51 gene might be belonging to the other members of this complex. 
The other gene investigated in this study was for the OXA-23 enzyme. This is one of the 
most widespread genes, encoding for resistance(4). No studies to detect these genes in 
Indian isolates have been carried out.  A study done in Argentina showed the presence of 
OXA-23 in 63.4% (n=41)(81) of the carbapenem resistant isolates. Another study done in 
China showed the presence of OXA-23 in 94.15% of the isolates (n=342) (82). In this 
study 73% of the tested isolates (n=80), were positive for OXA-23. 
 There were four carbapenem resistant isolates which were negative for both OXA-51 
and OXA-23. The resistance mechanism in these isolates could be due to presence of 
other mechanisms described such as presence of carbapenemases, efflux pumps, and loss 
of outer membrane porin channel. 
Eighteen of the isolates were randomly chosen and subjected to analysis for detection of 
other genes which encode for resistance to other classes of anti microbial agents. This 
revealed the presence of class I integrons in eleven of the tested isolates. No studies have 
been carried out in India to identify integrons in the isolates here. Turton et al have found 
Class I integrons to be present in all isolates tested by them (26). Another study done in 
Spain showed 84% (n=70), of the strains to be positive for Class I integrons (83).  
The mortality in the patients infected with carbapenem resistant strains was determined in 
this study. There was a significant association noted between the two and was found to be 
statistically significant.  A study done in 2007 had proven that infection with MDR 
Acinetobacter predisposed to longer hospital stay and higher mortality (84). Another 
study done in Korea has proven that the thirty day mortality rate in patients suffering 
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from imipenem resistant Acinetobacter bacteraemia was 57.5% as compared to27.5% in 
those infected with susceptible strains (85). 
Impact of tigecycline resistance on mortality was assessed in the carbapenem resistant 
isolates. No significant association was found in our patients. Studies linking infection 
with a tigecycline resistant strain to outcome of the disease process in the patients has not 
been carried out any where else in the world.  
Also the mortality of the patients infected with pan drug resistant isolates was 
determined. It was found that there was no correlation between the two. This may be 
explained on the basis of the other co morbid processes going on the patient- 
hemodynamic instability, renal or cardiovascular compromise. No studies to correlate pan 
drug resistance with mortality have been done. 
Clinical Pulmonary Infection Score (CPIS) was calculated for the patients who had 
nosocomial pneumonia. This was further correlated with the outcome of the patient as in 
mortality or cure. It was found that with an increase in the CPIS, there was an increase in 
mortality, which was found to be statistically significant. No studies relating the CPIS 
with mortality have been undertaken in India. A study done in Ankara, Turkey had shown 
no correlation between CPIS and mortality (60). 
The Charlson co morbidity index was calculated for the patients in this study. This index 
takes into account a host of chronic co-morbid conditions which can influence the 
outcome of the disease process. The index was compared with the mortality of the 
patients, so as to gauge the significance of the chronic conditions in our patients. It was 
found that the chronic co-morbid conditions did not influence the outcome in our 
patients, thus indicating that the infection with A.baumannii in a nosocomial set up was 
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an independent predictor of mortality and not statistically associated with the chronic 
com-morbid conditions. No studies have so far been done to assess the effect of chronic 
co-morbid conditions on patients infected with A.baumannii. 
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CONCLUSIONS 
Conclusions and summary  
The total number of nosocomial A.baumannii isolates included in this study was one 
hundred.  78% of the isolates included in this study were isolated from nosocomial 
pneumonia. This indicates that A. baumannii is a leading cause of nosocomial 
pneumonia. 
The resistance to β-lactam agents was 100%, to amino glycosides and fluoroquinolones 
was 85% and to the β-lactam +β-lactamase inhibitor combination was 79%.  The number 
of PDR A.baumannii was 57% and MDR A.baumannii was 43%. The number of isolates 
being resistant to so many anti microbial agents is indeed concerning.  
Efficacy of the newer drug being advocated as a treatment option for carbapenem 
resistant A.baumannii   - Tigecycline was evaluated in our study isolates. None of the 
isolates tested, were susceptible to Tigecycline with only seven of the isolates being 
intermediately susceptible. The lack of standard break points for defining susceptibility or 
resistance has also partially lead to varied results across the world. 
 Susceptibility to the drugs of renewed interest (Polymyxins and Sulbactam) was assessed 
by determining the MIC using the agar dilution method. Susceptibility to Polymyxins 
was 95% of the carbapenem resistant isolates (n=80). This was in accordance to the 
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reports published world wide. Surprisingly the susceptibility to Sulbactam in the 
carbapenem resistant isolates was only 11%. This high level of resistance is an area of 
concern. 
 Of the one hundred isolates tested in this study, OXA-51 was present in 92% of the 
isolates. This further supports the hypothesis of using OXA-51 as a molecular marker for 
the identification of A.baumannii.  The other gene encoding for resistance OXA-23 was 
present in 73% of the carbapenem resistant isolates tested. This proves the resistance 
mechanisms in our isolates are similar to those reported across the world. The presence of 
Class I integrons in eleven of the eighteen representative isolates tested, gives a 
preliminary idea with regard to the other mechanisms encoding for resistance across 
various classes of anti-microbial agents. Further studies need to be done on a larger 
sample size.   
The randomly tested isolates were negative for the other ESBL’s, transmissible Amp C 
genes, Class A, B, and other Class D (OXA-58 and OXA-24) carbapenemases. Also they 
were negative for quinolone resistance determinants.  
Infection with carbapenem resistant A.baumannii significantly increased the risk of 
mortality in the patients included in the study. Thus it proves the fact that infections with 
a carbapenem resistance isolate do affect the clinical outcome of the patient. Increase in 
CPIS was significantly associated with increase in mortality in the patients suffering from 
nosocomial pneumonia. The chronic co-morbid conditions did not significantly increase 
the risk of mortality in the patients included in this study. 
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ANNEXTURE 2 
PROFORMA FOR CARBAPENEM RESISTANT  HOSPITAL ACQUIRED 
ACINETOBACTER BAUMANNII STUDY 
 
1. NAME      AGE  SEX 
 
2. HOSPITAL NUMBER    WARD UNIT 
 
 
3. OCCUPATION 
 
4. DATE OF ADMISSION    DATE OF DISCHARGE/DEATH 
 
5. DATE OF NOSOCOMIAL INFECTION DEVELOPING: 
 
 
6. DATE OF SURGICAL PROCEDURE IF ANY: 
 
7. DATE OF TRANSFER TO ICU IF ANY: 
 
 
8. ADMISSION DIAGNOSIS: 
 
9. OUTCOME- CURED    EXPIRED     DISCHARGED 
 
 
10. CLINCAL DATA 
  
1. FEVER AT ADMISSION:  YES/NO 
 
2. WHAT NOSOCOMIAL INFECTION DOES THE PATIENT HAVE: 
 
DOES THE PATIENT FULFILL THE FOLLOWING DEFINITIONS?IF SO CIRCLE THE 
FEATURES THAT THE PATIENT HAS 
Nosocomial urinary tract infection: 
Patients having at least one of the following signs and symptoms with no other 
recognizable cause of fever, with fever > 38°C,urgency,frequency,dysuria or 
suprapubic tenderness and a positive urine culture ie > 105 organisms/cm3 of 
urine with no more than 2 microorganisms grown on culture with symptoms 
occurring more than 48 hrs after hospital stay. 
 
           Nosocomial Septicemia 
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Patients who develop fever, hypotension, tachycardia, tachypnoea after 48 hours 
after admission to the hospital, the pathogen being cultured in one or more blood 
cultures and having no relation to an infection at another site.   
 
Nosocomial meningitis 
Patients who develop fever, headache, neck pain, vomiting, altered sensorium 
after a neurosurgical procedure or any procedure that could have led to 
Nosocomial meningitis, with no other cause for fever. 
 
Nosocomial deep abscesses  
Patients who develop fever, deep abscesses and pain after any surgical 
procedure or any procedure that could have led to a Nosocomial deep abscess. 
 
IV Catheter tips and Post operative pyogenic isolates 
Patients who develop fever, thrombophlebitis ,evidence of sepsis  following the 
use of an IV catheter or post operative infections that have developed 48 hrs after 
admission. 
 
Nosocomial Pneumonia: 
Patients who develop new onset pneumonia more than 48 hours after admission 
to the hospital. The clinical features include fever, leucocytosis,new onset 
purulent sputum/respiratory secretions, new onset or worsening cough or 
breathlessness, bronchial breath sounds, or worsening gas exchange, a chest 
radiograph with new or progressive infiltrate ,consolidation or cavitation (1). 
 
 
 
CPIS(MODIFIED SCORE) 
 
CPIS POINTS 0 1 2 
Tracheal Secretions Rare Abundant Abundant+purulent 
Chest X-ray infiltrates No infiltrate Diffused Localized 
Temperature >97.4 and <101.2 >101.2 and<102.2 >102.2 or <96.8 
Leukocytes/mm3 >4000and<11000 <4000or>11000 <4000or>11000+band
PAo2/ Fio2,mmHg >240or ARDS  <240 or no ARDS 
Microbiology Negative  Positive 
 
Total score= 
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11. MICROBIOLOGY SECTION 
  
SOURCE 
 
12. AST DATA OF THE ORGANISM 
 
 
         RESULTS 
CTX  
CZD  
CPI  
IMP  
MERO  
GENTA  
AK  
LEVO  
CIPRO  
MAGNEX  
TIMENTIN  
PIP/TAZO  
SXT  
CHLORO  
TIGE  
COLISITIN  
PB300  
 
MIC  
PB300 
 
SULBACTUM 
 
13. BIOCHEMICAL SPECIATION 
  
OF GLUCOSE  
NITRATE REDUCTION  
ARGININE DIHYDROLASE  
MALONATE UTILISATION  
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14. MULTIPLEX  P.C.R  RESULTS 
 
  
OXA 23  
OXA 51  
 
 
 
